Note: Descriptions are shown in the official language in which they were submitted.
CA 02202075 2000-07-26
WO 96111949 PCTJ1895I00971
-1-
ANALOGS OF KERATINOCYTE GROWTH FACTOR, NUCLEIC ACIDS
ENCODING SUC:H ANALOGS, PROCESSES OF MAKING
.AND METHODS OF USING
The present invention relates to recombinant
DNA technology and protein engineering. Specifically,
recombinant DDJA methodologies have been applied to
generate polyF~eptide analogs of keratinocyte growth
factor (RGF), a potent mitogen of non-fibroblast
epithelial ce7.1 growth, wherein the analogs have
improved stability as compared to that of the parent
KGF.
The complex process of tissue generation and
regeneration is mediated by a number of protein factors
sometimes referred to as soft tissue growth factors.
These molecules are generally released by one cell type
and act to influence proliferation of other cell types.
(Rubin et a1. (1989), Proc. Nat'1. Acad. Sci. USA,
,$x:802-806). Some soft tissue growth factors are
secreted by particular cell types and influence the
proliferation, differentiation, and/or maturation of
responsive cells in the development of multicellular
organisms (Finch et a1. (1989), Science, x:752-755).
In addition tc> their roles in developing organisms, some
are significant in the continued health and maintenance
of more matures systems. For instance, in mammals, there
are many systems where rapid cell turnover occurs. Such
systems include the skin and the gastrointestinal tract,
both of which are comprised of epithelial cells.
Included within this group of soft tissue growth factors
is a protein family of fibroblast growth factors (FGFs).
There are currently eight known FGF family
members which share a relatedness among primary
CA 02202075 1998-03-06
WO 96/11949 PCT/IB95/00971
- 2 -
structures: basic fibroblast growth factor, bFGF
(Abraham et a1. (1986), E1~0 J., 5:2523-2528); acidic
fibroblast growth factor, aFGF (Jaye et a1. (1986),
Science, 233:541-545); int-2 gene product, int-2
(Dickson & Peters (1987), Nature, 326:833); hst/kFGF
(Delli-Bovi et a1. (1987), Cell, 50:729-737) and Yoshida
et a1. (1987), Proc. Natl. Acad. Sci. USA, 84:7305-
7309); FGF-5 (than et al. (1988), Mol. Cell. Biol.,
8:3487-3495); FGF-6 (Marics et a1. (1989), Oncogene,
4:335-340); keratinocyte growth factor (Finch et a1.
(1989), Science, 24:752-755); and hisactophilin
(Habazzettl et a1. (1992), Nature, 359:855-858).
Among the FGF family of proteins, keratinocyte
growth factor ("KGF") is a unique effector of non-
fibroblast epithelial (particularly keratinocyte) cell
proliferation derived from mesenchymal tissues. The
term "native KGF" refers to a natural human (hKGF) or
recombinant (rKGF) polypeptide (with or without a signal
sequence) as depicted by the amino acid sequence
presented in SEQ ID N0:2 or an allelic variant thereof.
[Unless otherwise indicated, amino acid numbering for
molecules described herein shall correspond to that
presented for the mature form of the native molecule
(i.e., minus the signal sequence), as depicted by amino
acids 32 to 194 of SEQ ID N0:2.]
Native KGF may be isolated from natural human
sources (hKGF) or produced by recombinant DNA techniques
(rKGF) (Finch et a1. (1989), supra; Rubin et al. (1989),
supra; Ron et a1. (1993), The Journal of Biological
Chemistry, 268(4):2984-2988; and Yan et a1. (1991), In
Vitro Cell. Dev. Biol., 27A:437-438).
It is known that native KGF is relatively
unstable in the aqueous state and that it undergoes
chemical and physical degradation resulting in a loss
of biological activity during processing and storage
(Chen et a1.(1994), Pharmaceutical Research, 11:1582-
CA 02202075 1998-03-06
WO 96111949 PCT/1895/00971
- 3 -
1589). Native KGF is prone also to aggregation at
elevated temperatures and it becomes inactivated under
acidic conditions (Robin et a1. (1989), Proc. Natl.
Acad. Sci. USA, 86:802-806). Aggregation of native KGF
in aqueous solution also results in inactivated protein.
This is disadvantageous because such loss of activity
makes it impractical to store aqueous formulations of
native KGF proteins for extended periods of time or to
administer the protein over extended periods. Moreover,
this is particularly problematic when preparing
pharmaceutical formulations, because aggregated proteins
have been known to be immunogenic (Cleland et a1.
(1993), Crit. Rev. Therapeutic Drug Carrier Systems,
10:307-377; Bobbins et al. (1987), Diabetes, 36:838-845;
and Pinckard et a1. (1967), Clin. Fxp. Immunol., 2:331-
340).
Native KGF comprises five cysteine residues,
namely amino acids 1, 15, 4~, 102, and 106 (Finch et a1.
(1989), Science, 24:752-755). Although the cysteine
content of native KGF was reported, what has not been
reported are the roles played by cysteine residues with
respect to activity (e. g., essentiality to biological
activity) and tertiary structure (e.g., proclivity to
form undesirable intermolecular or intramolecular
disulfide bonds). Thus, there is no prior art teaching
of which, if any, cysteine residues are essential or are
involved in undesirable disulfide bond formation, making
the protein susceptible to aggregation and/or
instability.
In order to attempt to improve or otherwise
' alter one or more of the characteristics of native KGF,
protein engineering may be employed. Recombinant DNA
technology has been utilized to modify the sequences of
native KGF.
Ron et a1. (1993), J. Biol. Chem.,
268(4):2984-2988 reported modified KGF polypeptides
CA 02202075 1998-03-06
WO 96/11949 PCTIIB95/00971
- 4 -
having 3, 8, 27, 38 or 49 amino acids deleted from the
N-terminus. Those polypeptides missing 3, 8, or 27
N-terminal residues retained heparin binding ability;
the others did not. Also, the polypeptides missing _
3 and 8 residues were reported as being fully active,
whereas the form missing 27 residues was 10-20 fold less
mitogenic, and the forms lacking 38 or 49 amino acids
did not have mitogenic activity. The stability of the
modified KGF polypeptides was not discussed or otherwise
reported.
Published PCT application no. 90/08771, supra,
--- also reported the production of a chimeric protein
wherein about the first 40 N-terminal amino acids of the
mature form of native KGF were combined with the C-
terminal portion (about 140 amino acids) of aFGF. The
chimera was reported to target keratinocytes like KGF,
but it lacked susceptibility to heparin, a
characteristic of aFGF but not KGF. The stability of
the chimera was not discussed or otherwise reported.
Thus, the literature has not reported a
modified KGF molecule having significantly improved
stability relative to native KGF. Moreover, the
literature has not reported sufficient teachings or
evidence to provide a reasonable expectation of
successfully generating KGF molecules with such
desirable characteristics.
Generally, the effects upon biological
activity of any amino acid change upon a protein will
vary depending upon a number of factors, including the
three-dimensional structure of the protein and whether
or not the modifications are to the receptor binding
region of the primary sequence of the protein. As
neither the three-dimensional structure nor the receptor
binding region on the primary structure of native KGF
has been published, the knowledge within the art does
not permit generalization about the effects of amino
CA 02202075 2000-07-26
WO 96/11949 PGTIIB95I00971
- 5 -
acid modifications t:o native KGF based upon the effects
of amino acid modifications on even commonly categorized
proteins.
It is the object of this invention to provide
polypeptide molecules encoding such analogs that exhibit
enhanced stability (e.g., when subjected to typical pH,
thermal and/or other storage conditions) as compared to
native RGF.
:3ummarv of the Invention
The present invention provides novel, biologically active
polypeptide analogs of KGF. For purposes of this invention,
the term "KGF" includes native KGF and proteins characterized
by a peptide sequence substantially the same as the peptide
sequence of native KGF which retains cysteine residues
corresponding to Cys~ and Cysts of native KGF (Cys32 and Cys46 of
SEQ ID N0:2) and which retains some or all of the biological
activity of native KGF, particularly non-fibroblast epithelial
cell proliferation. When making reference to Figures 4, 7-24
and 37-50 and the specific amino acid position, the initial
methionine in the .aequence should be considered residue number
"0".] By "characterized by a peptide sequence substantially
the same as the peptide sequence of native KGF" is meant a
peptide sequence whi~~h is encoded by a DNA sequence capable of
hybridizing to nucleotides 201 to 684 of SEQ ID N0:1,
preferably under st:r.ingent hybridization conditions.
The determination of a corresponding amino
acid position between two amino acid sequences may be
determined by aligning the two sequences to maximize
matches of residues including shifting the amino and/or
carboxyl terminus, introducing gaps as required and/or
deleting residues present as inserts in the candidate.
Database searches, sequence analysis and manipulations
may be performed using one of the well-known and
routinely used sequence homology/identity scanning
CA 02202075 2000-07-26
WO 96111949 p~~l
- 6 -
algorithm programs (e. g., Pearson and Lipman (1988),
Proc. Nat:l. Aca~d. Sci. U.S.A., $x:2444-2448; Altschul et
a1. (199C), J. Mol. Biol., x:403-410; Lipman and
Pearson (1985). Science, x:1435 or Devereux et a1.
5 (1984) , r~uc. Acids Res., x,2,:387-395) .
Stringent conditions, in the hybridization
context, will b,e stringent combined conditions of salt,
temperature, organic solvents and other parameters
typically controlled in hybridization reactions.
10 Exemplar~~ stringent hybridization conditions are
hybridization in 4 X SSC at 62-67° C., followed by
washing i.n 0.:1 X SSC at 62-67° C. for approximately an
hour. Alternatively, exemplary stringent hybridization
conditioris are 'hybridization in 45-55$ formamide, 4 X
15 SSC at 40-45°C. [See, T. Maniatis et. al., Molecular
Cloning LA Laboratory Manual); Cold Spring Harbor
Laboratozy (1982), pages 387 to 389).
Thus, the proteins include allelic variations,
or deleti.on(s), substitutions) or insertions) of amino
20 acids, including fragments, chimeric or hybrid molecules
of native: KGF. One example of KGF includes charge
change polypeptides wherein one or more of amino acid
residues 41-154 of native RGF (preferably residues Arg4l,
G 1n43, L~~s55~ Lys95~ Lys128~ Asn137, G1n138, Lys139,
25 Arg144 ~ Lys147 ~ G1n152 ~ Lys153 or X154 ) ~e deleted or
substituted with a neutral residue or negatively charged
residue :elected to effect a protein with a reduced
positive charge
specifically
30 includin<~ R(144)Q, a KGF having a substitution of
glutamine for arginine at amino acid positions 144 of
native Ke;F. Ar.~other example of KGF includes proteins
generated by substituting at least one amino acid having
a higher loop-forming potential for at least one amino
35 acid wit)ain a loop-forming region of Asn115_gis116-
Tyr117_A;~n118_~~hr119 of native KGF
CA 02202075 2000-07-26
WO 96111949 PCTIj893/00971
_
specifically including H(116)G, a RGF having a
substitution of gl;ycine for histidine at amino acid
position 116 of native KGF. A still further example
includes proteins having one or more amino acid
substitutions, deletions or additions within a region of
123-133 (amino acids 154-164 of SEQ ID N0:2) of native
KGF; these proteins may have agonistic or antagonistic
activity.
Surprisingly, it has been discovered when a
KGF molecule fi.e., parent molecule) having cysteine
residues corresponding (as determined using techniques
described aboz~e) to Cyst and Cysl5 of native KGF
(cysteine residues 32 and 46 of SEQ ID N0:2) is modified
by replacing the corresponding cysteines, the resultant
KGF analog has. improved stability as compared to the
parent molecule. Preferably, in addition to having
increased sta~~ility, the invention is directed to those
analogs which also exhibit full biological activity
(i.e., at least substantially similar receptor binding
or affinity) a.s compared to native KGF.
In ~~nother aspect of the invention, purified
and isolated nucleic acid molecules encoding the various
biologically active polypeptide analogs of KGF are
described. In. one embodiment, such nucleic acids
comprise DNA molecules cloned into biologically
functional plasmid o:r viral vectors. In another
embodiment, nucleic acid constructs may then be utilized
to stably transform a procaryotic or eucaryotic host
cell. In still another embodiment, the invention
involves a process wherein either a procaryotic
(preferably E. coli) or eucaryotic host cell stably
transformed with a nucleic acid molecule is grown under
suitable nutrient conditions in a manner allowing the
expression of the KGF analog. Following expression, the
CA 02202075 1998-03-06
WO 96/11949 PGTlIB95/00971
_ g _
resultant recombinant polypeptide can be isolated and
purified.
A further aspect of the invention concerns
pharmaceutical formulations comprising a therapeutically
effective amount of a KGF analog and an acceptable
pharmaceutical carrier. Such formulations will be
useful in treating patients afflicted with epithelial
diseases and injuries.
In this vein, another aspect relates to
methods of stimulating epithelial cell growth by
administering to a patient a therapeutically effective
amount of a KGF analog. In one embodiment,
non-fibroblast epithelial cells are the cells whose
proliferation is stimulated. Such epithelial cells
include various adnexal cells, pancreatic cells, liver
cells, and mucosal epithelium in the respiratory and
gastrointestinal tracts.
CA 02202075 2000-07-26
WO 96111949 PCTIIB95100971
- 9 -
brie DeSCriDtiOn of the Fivures
Figures 1A and 1.B show the nucleotide (SEQ ID NO:1)
and amino acid (SEQ ID N0:2) sequences of native KGF
(the nucleotides encoding the mature form of native KGF
is depicted b~,r bases 201 to 684 of SEQ ID NO:1 and the
mature fozm o:E KGF i.s depicted by amino acid residues 32
to 194 of SEQ ID N0:2).
Figures 2A, 2B and 2C show the plasmid maps of
pCFM1156, pCFT41.656 and pCFM3102, respectively.
Figure 3 :shows the nucleotide (SEQ ID N0:3)
and amino acid (SEQ ID N0:4) sequences of the construct
RSH-KGF.
Figure 4 shows the nucleotide (SEQ ID N0:5)
and amino acid (SEQ ID N0:6) sequences of the construct
contained in plasmid, KGF.
Fig.ire 5 :chows the chemically synthesized
OLIGOs (OLIGO)k6 through OLIGO#11; SEQ ID N0:12-17,
respectively) used to substitute the DNA sequence
between a Kpn7: site and an EcoRI site (from amino acid
positions 46 t:o 85 of SEQ ID No:6) in the construct
contained in plasmid KGF to produce the construct in
plasmid KGF(dsd).
Figure 6 shows the chemically synthesized
OLIGOs (OLIGO~kl2 through OLIGO#24; SEQ ID N0:18-30,
respectively) used to construct KGF (codon optimized).
Figure 7 shows the nucleotide (SEQ ID N0:31)
and amino acid (SEQ ID N0:32) sequences of C(1,15)S, a
KGF analog having substitutions of serine for cysteine
at amino acid positions 1 and 15 of native KGF.
Fig~ire 8 shows the nucleotide (SEQ ID N0:33)
and amino acid (SEQ ID N0:34) sequences of L1N3/C(15)S, a
KGF analog having a deletion of the first 3 amino acids
of the N-terminus and a substitution of serine for
cysteine at aauno acid position 15 of native KGF.
CA 02202075 1998-03-06
WO 96111949 PCT11895100971
- 10 -
Figure 9 shows the nucleotide (SEQ ID N0:35)
and amino acid (SEQ ID N0:36) sequences of ~N3/C(15)-, a
KGF analog having a deletion of the first 3 amino acids
of the N-terminus and a deletion of cysteine at amino
acid position 15 of native KGF.
Figure 10 shows the nucleotide (SEQ ID N0:37)
and amino acid (SEQ ID N0:38) sequences of ON8/C(15)S, a
KGF analog having a deletion of the first 8 amino acids
of the N-terminus and a substitution of serine for
cysteine at amino acid position 15 of native KGF.
Figure 11 shows the nucleotide (SEQ ID N0:39)
and amino acid (SEQ ID N0:40) sequences of ~1V8/C(15)-, a
KGF analog having a deletion of the first 8 amino acids
of the N-terminus and a deletion of cysteine at amino
acid position 15 of native KGF.
Figure 12 shows the nucleotide (SEQ ID N0:41)
and amino acid (SEQ ID N0:42) sequences of ~1V15, a KGF
analog having a deletion of the first 15 amino acids of
the N-terminus of native KGF.
Figure 13 shows the nucleotide (SEQ ID N0:43)
and amino acid (SEQ ID N0:44) sequences of O1V16, a KGF
analog having a deletion of the first 16 amino acids of
the N-terminus of native KGF.
Figure 14 shows the nucleotide (SEQ ID N6:45)
and amino acid (SEQ ID N0:46) sequences of DiVl7, a KGF
analog having a deletion of the first 17 amino acids of
the N-terminus of native KGF.
Figure 15 shows the nucleotide (SEQ ID N0:47)
and amino acid (SEQ ID N0:48) sequences of ~N18, a KGF
analog having a deletion of the first 18 amino acids of .
the N-terminus of native KGF. -
Figure 16 shows the nucleotide (SEQ ID N0:49)
and amino acid (SEQ ID N0:50) sequences of ~N19, a KGF
analog having a deletion of the first 19 amino acids of
the N-terminus of native KGF.
CA 02202075 1998-03-06
WO 96/11949 PCT/1895/00971
- 11 -
Figure 17 shows the nucleotide (SEQ ID N0:51)
_ and amino acid (SEQ ID N0:52) sequences of ~1V20, a KGF
analog having a deletion of the first 20 amino acids of
the N-terminus of native KGF.
Figure 18 shows the nucleotide (SEQ ID N0:53)
and amino acid (SEQ ID N0:54) sequences of ~1V21, a KGF
analog having a deletion of the first 21 amino acids of
the N-terminus of native KGF.
Figure 19 shows the nucleotide (SEQ ID N0:55)
and amino acid (SEQ ID N0:56) sequences of ~N22, a KGF
analog having a deletion of the first 22 amino acids of
--- the N-terminus of native KGF.
Figure 20 shows the nucleotide (SEQ ID N0:57)
and amino acid (SEQ ID N0:58) sequences of ON23, a KGF
analog having a deletion of the first 23 amino acids of
the N-terminus of native KGF.
Figure 21 shows the nucleotide (SEQ ID N0:59)
and amino acid (SEQ ID N0:60) sequences of ~N24, a KGF
analog having a deletion of the first 24 amino acids of
the N-terminus of native KGF.
Figure 22 shows the nucleotide (SEQ ID N0:61)
and amino acid sequences (SEQ ID N0:62) of
C(1,15)S/R(144)E, a KGF analog having substitutions of
serine for cysteine at amino acid positions 1 and 15 and
a substitution of glutamic acid for arginine at amino
acid position 144 of native KGF.
Figure 23 shows the nucleotide (SEQ ID N0:63)
and amino acid (SEQ ID N0:64) sequences of
C(1,15)S/R(144)Q, a KGF analog having substitutions of
. 30 serine for cysteine at amino acid positions 1 and 15 and
a substitution of glutamine for arginine at amino acid
position 144 of native KGF.
Figure 24 shows the nucleotide (SEQ ID N0:65)
and amino acid (SEQ ID N0:66) sequences of ON23/R(144)Q,
a KGF analog having a deletion of the first 23 amino
acids of the N-terminus and a substitution of glutamine
CA 02202075 2000-07-26
WO 96!11949 p~~l
- 12 -
for argin:ine at amino acid position 144 of native KGF.
Figure 25 shows the amount of remaining
soluble p::otein when native KGF and C(1,15)S were stored
in 20 mM 1~1a phosphate, 0.15 M NaCl, pH 7.0 at 37'C for
5 27 hrs.
10 Figure 26 shows the amount of remaining soluble
protein when native KGF, ~N15 and C(1,15)S were stored in 50
mM NaP04, 0.15 M NaCl, pH 7.0 at 37°C for 27 hrs.
Figure 27 shows the amount of soluble protein of
native KGF, C(1,15)S, C(1,15)S/R(144)E and C(1,15)S/R(144)Q,
15 determined by size exclusion HPLC, as a function of incubation
time at 3'7°C.
Figure 28 shows the estimated melting temperature
(Tm) as a function of pH for native KGF, C(1,15)S,
C(1,15)S/R(144)Q and C(1,15)S/R(144)E.
20 Figuw~e 29 shows a typical profile of mitogenic
activity of C11,15)S determined by measuring the
incorporation oi: [3H]-Thymidine during DNA synthesis by
comparing it to a native RGF standard curve.
Figure 30 shows a typical profile of the
25 mitogenic activ-.Lty of AN15 determined by measuring the
incorporation o:E [3H]-Thymidine during DNA synthesis and
by comparing it to a native RGF standard curve.
Figure 31 shows a typical profile of the
mitogenic activity of ~N23 determined by measuring the
30 incorporation o:E [3H]-Thymidine during DNA synthesis and
by comparing it to a native KGF standard curve.
Figure' 32 shows a typical profile of the
mitogenic activity of AN23/R(144)Q detexinined by
measuringr the incorporation of [3H]-Thymidine during DNA
35 synthesis; and by comparing it to a native KGF standard
curve.
CA 02202075 2000-07-26
WO 96111949 PGT/IB95I00971
- 13 -
Figure 33 shows a typical profile of the
mitogenic activity of C(1,15)S/R(144)Q determined by
measuring the incorporation of [3H]-Thymidine during DNA
synthesis and by comparing it to a native KGF standard
curve.
Figure 34 shows a typical profile of the
mitogenic activity of C(1,15)S/R(144)E determined by
measuring the incorporation of [3H]-Thymidine during DNA
synthesis and by comparing it to a native KGF standard
curve .
Figure 35 shows the effects of native KGF, KGF-a,
~N15, C(1,15)S and
~N23 on serum chemistries.
Figure 3E. shows the nucleotide (SEQ ID N0:77)
and amino acid. :ID N0:78) sequences of C(1,15,40)S,
(SEQ
15a KGF analog havingsubstitutions of serine for cysteine
at amino acid positions
1, 15 and 40 of
native RGF.
Figure 3'7 shows the nucleotide (SEQ ID N0:79)
and amino acid. :ID N0:80) sequences of C(1,15,102)S,
(SEQ
a KGF analog havingsubstitutions of serine for cysteine
20at amino acid positions
1, 15 and 102 of
native KGF.
Figure 3E1 shows the nucleotide (SEQ ID N0:81)
and amino acid. :ID N0:82) sequences of
(SEQ
C(1,15,102,106)S, ~KGF analog having substitutions of
a
serine for cysteineat amino acid positions 1. 15, 102
25and 106 of native
KGF.
Figure 3~~ shows the nucleotide (SEQ ID N0:83)
and amino acid. :ID N0:84) sequences of AN23/N(137)E,
(SEQ
a KGF analog havinga deletion of the first 23 amino
acids of the N~-terminus
and a substitution
of glutamic
30acid for aspar~agineat amino acid position 137 of native
RGF.
Figure 40 shows the nucleotide (SEQ ID N0:85)
and amino acid'. (SEQ :ID N0:86) sequences of AN23/K(139)E,
a RGF analog having a deletion of the first 23 amino
35 acids of the N~-terminus and a substitution of glutamic
CA 02202075 2000-07-26
WO 96/11949 PCTI1895100971
- 14 -
acid for lysine at amino acid position 139 of native
KGF.
Figure' 41 shows the nucleotide (SEQ ID N0:87)
and amino acid (SEQ ID N0:88) sequences of ~N23/K(139)Q,
5 a KGF analog having a deletion of the first 23 amino
acids of the N-terminus and a substitution of glutamine
for lysine at amino acid position 139 of native KGF.
Figure 42 shows the nucleotide (SEQ ID N0:89)
and amino acid (SEQ ID N0:90) sequences of DN23/R(144)A,
10 a RGF analog having a deletion of the first 23 amino
acids of the N-terminus and a substitution of alanine
for arginine at amino acid position 144 of native KGF.
Figure 43 shows the nucleotide (SEQ ID N0:91)
and amino acid (SEQ ID N0:92) sequences of AN23/R(144)E,
15 a RGF analog having a deletion of the first 23 amino
acids of the N-terminus and a substitution of glutamic
acid for arginine at amino acid position 144 of native
KGF.
Figure 44 shows nucleotide (SEQ ID N0:93)
the
20 and amino acid (SEQID N0:94)sequences of 11N23/R(144)L,
a RGF analog havinga deletionof the first 23 amino
acids of the N-terminus substitution of leucine
and a
for axgin.ine at ition 144 of native
amino acid pos KGF.
Figure 45 shows nucleotide (SEQ ID IQ0:95)
the
25 and amino acid (SEQID N0:96)sequences of ~N23/K(147)E,
a KGF analog havinga deletionof the first 23 amino
acids of the N-terminus substitution of glutamic
and a
acid for lysine position 147 of native
at amino acid
KGF.
30 Figure 46 shows nucleotide (SEQ ID N0:97)
the
and amino acid (SEQID N0:98)sequences of ON23/K(147)Q,
a KGF analog havinga deletion
of the
first
23 amino
acids of the N-terminus substitution of glutamine
and a
for lysirve at aminoacid position
147 of
native
RGF.
35 Figure 47 shows nucleotide (SEQ ID N0:99)
the
and amine acid (SEQID NO:100)sequences of
CA 02202075 2000-07-26
WO 96J11949 PCTI1895I00971
- 15 -
~N23/K(153)E, a KGF analog having a deletion of the
first 23 amino acids of the N-terminus and a
substitution of glut~3znic acid for lysine at amino acid
position 153 of native KGF.
Figure 4~3 shows the nucleotide (SEQ ID NO:101)
and amino acid (SEQ .CD N0:102) sequences of
~N23/K(153)Q, a KGF analog having a deletion of the
first 23 amino acids of the N-terminus and a
substitution of gluteunine for lysine at amino acid
position 153 of native KGF.
Figure 49 .shows the nucleotide (SEQ ID N0:103)
i-Y- and amino acid (SEQ :CD N0:104) sequences of
~N23/Q(152)E/K(153)E,, a RGF analog having a deletion of
the first 23 amino acids of the N-terminus and a
substitution of gluteunic acid for glutamine at amino
acid position 152 of native KGF and glutamic acid for
lysine at amino acid position 153 of native KGF.
Figure 50 chows the effect of dN23 on
streptozotocin-induced diabetes in Sprague-Dawley rats.
In accordance with the present invention,
novel analogs ~~f KGF are provided. It has now been
determined that four of the cysteine residues of native
KGF (G~ssl and ~'rysl5, and Cyslo2 and C~rslo6) are involved
in the formation of t:wo disulfide bridges. Cys4o is not
involved in intramole:cular disulfide formation. Hence,
KGF contains t~ao small disulfide loops separated by
almost 90 amine acid:;. Based upon first principals, the
determination ~~f whic:h cysteine residues are involved in
the disulfide lbridge~c suggests which cysteines are free
to form undesirable i.ntezmoleculax crosslinks or
intramolecular bonds that cause the protein to adopt an
undesirable tertiary structure (e. g., a conformation
that reduces the activity of the protein).
CA 02202075 1998-03-06
WO 96111949 PCTI1895100971
- 16 -
Surprisingly, it has been found that modifying
a KGF by deleting or substituting amino acid residues .
for the cysteine residues corresponding to positions 1
and 15 of KGF (positions 32 and 46 of SEQ ID N0:2)
produces a KGF analog having substantially improved
stability (i.e., reduced problems caused by improper
refolding, intermolecular disulfide formation and/or
protein aggregation). For example, the KGF analogs will
generally be purified in a greater yield of soluble,
correctly folded protein. Moreover, once the material
is purified, it will be more stable to pH, temperature,
etc. as compared to the stability of the parent
molecule. Although not intended to be bound by theory,
it is believed that Cyst and CyslS of KGF in addition to
_ 15 forming an intramolecular disulfide bridge and an N-
terminal disulfide loop, under certain conditions also
exist as free cysteines which are capable of forming
intermolecular disulfide bridges, resulting in protein
instability and aggregation. Moreover, it has been
discovered that deletion of the N-terminal disulfide
loop is not important for receptor binding or mitogenic
activity.
As used in this invention, a "KGF analog" or a
"polypeptide analog of KGF" shall mean any of the
described naturally and non-naturally occurring
polypeptides differing in structure from a KGF by
possessing modifications in peptide sequence
corresponding to the 24 amino acid N-terminus of the KGF
(amino acids 32 to 55 of SEQ ID N0:2), wherein Cysl and
CyslS of the KGF (amino acids 32 to 46 of SEQ ID N0:2) ,
are replaced or deleted. The manner by which the
cysteines are replaced or deleted is not significant and
includes, for example, polypeptide analogs incorporating
one or more amino acid deletions and/or substitutions.
Accordingly, the invention provides a family of novel
CA 02202075 1998-03-06
WO 96/11949 PCT/IB95/00971
- 17 -
keratinocyte growth factor proteins. This family
comprises several groups of proteins.
One group of KGF analogs includes molecules in
which the cysteines at positions 1 and 15 of a KGF are
replaced with amino acids, including those that do not
occur naturally in proteins. Strategies for generating
the substitution analogs include using site-directed
mutagenesis (Ho et a1. (1989), Gene, 77:51-59; Innis
et a1. "PRC Protocols", Academic Press, Inc., San Diego,
CA). [KGF analogs comprising an amino acid substitution
are referred to by the residue found at that position in
the mature protein (minus signal sequence) set forth in
SEQ ID N4:2, followed by that amino acid position in
parentheses and the new amino acid. For instance, an
analog comprising a cysteine to serine substitution at
amino acid position 15 of KGF (position 46 of SEQ ID
N0:2) is referred to as "C(15)S".] Preferably, the
cysteine is converted to a neutral amino acid such as
glycine, valine, alanine, leucine, isoleucine, tyrosine,
phenylalanine, histidine, tryptophan, serine, threonine
and methionine, with serine, threonine and alanine being
most preferred because of their chemical similarity to
cysteine. Example 1 details the generation of C(1,15)S
using partial gene synthesis (in conjunction with other
recombinant techniques) followed by recombinant
expression in a stably transfoz-med bacterial host.
Another group of KGF analogs includes
molecules that have the cysteines at positions 1 and 15
deleted from KGF. Different strategies may be employed
in developing such KGF analogs, such as N-terminal
truncations and site-specific deletions, or a
combination of both.
An "N-terminal truncation" refers to a
modification of a KGF wherein 1 to 24 N-terminal amino
acid residues of the KGF (amino acids 32 to 55 of SEQ ID
N0:2), including Cyst and CyslS, have been deleted.
CA 02202075 2000-07-26
WO 96111949 pCT~7~
- 18 -
[KGF anal~~gs comprising a truncation of amino acids will
be referred to by the residue deleted at that position
in the mature protein (minus signal sequence) set forth
in SEQ ID N0:2, beginning with the site of the deletion
5 and by the number of residues deleted. For instance, a
KGF analogs comprising an N-terminal truncation of 24
residues ~f trie KGF (residues 32-55 of SEQ ID N0:2) will
be referred to as a ~~i~T24" analog. ] Specifically
included within this group are DN23 analogs of native
10 KGF wherein one or more of amino acid residues 41-154
(amino acids 72--185 of SEQ ID N0:2), specifically
including amino acid residues 123-133 (amino acids 154-
164 of SEQ ID N0:2), aye deleted or substituted with a
neutral residue or negatively charged residue selected
15 to effect a protein with a reduced positive charge.
Preferred residues for modification are Arg4l, G1n43,
Lys55, Ly,s95, Lys128, Asn137~ G1n138~ Lys139, Arg144,
LySl4~, G.1n152, :Lys153 pr Thr154, with G1n138~ Lys139,
Az.g144, L,rs147, G1n152 or Lys153 being more preferred and
20 Arg144 being most preferred Also included within this
group are ~N23 analogs of native KGF having loop-forming
modifications within a loop-forming region of Asn115_
His116_Tyr117-A;~n118_Thr119 (amino acids 146-150 of SEQ
ID N0:2), prefe:cably including a charge-change
25 modification of amino acid residue 116, more preferably
the substitution of Gly at position 116. Further still,
included in this group are ~N23 analogs of native KGF
having ore or more amino acid substitutions, deletions
or additions within a region of 123-133 (amino acids of
30 154-164 ~~EQ ID N0:2) of native KGF.
Example 1 details the generation of systematic
N-terminal truncations accomplished using partial gene
synthesis;, in conjunction with other recombinant
techniques, followed by recombinant expression in a
35 stably transformed bacterial host. Such exemplified N-
terminal truncations include ~N15 to ~N24. Moreover,
CA 02202075 1998-03-06
WO 96111949 PCT/IB95100971
- 19 -
Example 3 details expression in mammalian cell culture
cells of DNA encoding native KGF and heterogeneous N-
terminal glycosylated isoforms, the purification of
preferably a glycosylated isoform having an N-terminal
truncation of amino acids 1-23 of the mature form of
native KGF.
In contrast, a site-specific deletion refers
to a modification of a KGF wherein one or more amino
acid residues (e.g., Cysl or CyslS) are removed. When a
Cyst or CyslS of the KGF is specifically deleted, the
analog is one amino acid shorter than the KGF. [KGF
analogs comprising an amino acid deletion are referred
to by the residue found at that position in the mature
protein (minus signal sequence) set forth in SEQ ID
N0:2, followed by that amino acid position in
parentheses, and a negative sign. For instance, an
analog within this group comprising a deletion of
cysteine at position 15 of the KGF (position 36 of SEQ
ID N0:2) is referred to as "C(15-)-".] The site-specific
deletions may be generated using site directed
mutagenesis, as described above.
Also included within this group are analogs in
which Cysl and CyslS of a KGF are removed through
truncation and deletion. For example, representative
KGF analogs comprise the truncation of the first three
amino terminal residues (Cys-Asn-Asp) of the KGF or the
truncation of the first eight amino acids (Cys-Asn-Asp-
Met-Thr-Pro-Glu-Gln) of the KGF coupled with the
deletion of cysteine at amino acid position 15 of KGF
(these analogs are referred to as ~N3/C(15)- and
ON8/C(15)-, respectively). As a methionine residue
occurs naturally at the fourth and ninth amino acid
position in native KGF, no additional Met codon is
required to enable proper initiation of translation.
A still further group includes molecules in
which the cysteines at positions 1 and 15 of KGF are
CA 02202075 2000-07-26
WO 96/11949
- 20 -
replaced through truncation and substitution. For
example, representative KGF analogs are AN3/C(15)S, and
DNS/C(15)~~. Such analogs comprise the truncation of the
first three amino-terminal residues of a KGF or the
deletion of the first eight amino-terminal residues of a
KGF coupled with the substitution of cysteine at amino
acid position 15 with another amino acid, for instance,
serine.
Tnlhen the KGF analogs are biologically
generated, i.e., are the products of cellular expression
as opposed to the products of solid state synthesis,
proteolytic or enzymatic derivatization of naturally-
occurring products, etc., the nucleic acids encoding
such polyF>eptides, will differ in one or more
nucleotides as compared to the native KGF nucleotide
sequence. Such polynucleotides may be expressed and the
resultant polypeptide purified by any one of a number of
recombinant technology methods known to those skilled in
the art.
DNA sequences coding for all or part of the
KGF analogs may include among other things the
incorporation of codons "preferred" for expression in
selected host cells (e.g.. "E. coli expression codons");
the provision of sites for cleavage by restriction
enzymes; wind the. provision of additional initial,
terminal, or intermediate nucleotide sequences (e.g., an
initial methioni.ne amino acid residue for expression in
E. coli cells), to facilitate construction of readily
expressed vectors.
The present invention also provides
recombina~at molecules or vectors for use in the method
of expression of: the polypeptides. Such vectors may be
comprised of DNA or RNA and can be circular, linear,
single-stranded or double-stranded in nature and can be_
naturall~c-occurring or assemblages of a variety of
components, be they naturally-occurring or synthetic.
CA 02202075 1998-03-06
WO 96111949 PCT/1895/00971
- 21 -
Many examples of such expression vectors are
known. The components of the vectors, e.g. replicons,
selection genes, enhancers, promoters, and the like, may
be obtained from natural sources or synthesized by known
procedures. In each case, expression vectors useful in
this invention will contain at least one expression
control element functionally associated with the
inserted nucleic acid molecule encoding the KGF
polypeptide analog. This control element is responsible
for regulating polypeptide expression from the nucleic
acid molecules of the invention. Useful control
elements include, for example, the lac system, the trp
system, the operators and promoters from phage ~,, a
glycolytic yeast promoter, a promoter from the yeast
acid phosphatase gene, a yeast alpha-mating factor, and
promoters derived from adenovirus, Epstein-Barr virus,
polyoma, and simian virus as well as those from various
retroviruses. However, numerous other vectors and
control elements suitable for procaryotic or eucaryotic
expression are known in the art and may be employed in
the practice of this invention.
Examples of suitable procaryotic cloning
vectors may include plasmids from E. coli (e. g. pBR322,
col E1, pUC, and the F-factor), with preferred plasmids
being pCFM1156 (ATCC 69702), pCFM1656 (ATCC 69576) and
pCFM3102 (described in the Examples section, below).
Other appropriate expression vectors of which numerous
types are known in the art for mammalian, insect, yeast,
fungal and bacterial expression can also be used for
this purpose. The transfection of these vectors into
appropriate host cells can result in expression of the
KGF analog polypeptides.
Host microorganisms useful in this invention
may be either procaryotic or eucaryotic. Suitable
procaryotic hosts include various E. coli (e. g., FM5,
HB101, DHSa, DH10, and MC1061), Pseudomonas, Bacillus,
CA 02202075 2000-07-26
WO 96!11949
- 22 -
and Strept:onryces strains, with E. coli being preferred.
Suitable e:ucaryotic host cells include yeast and other
fungi, insect cells, plant cells and animal cells, such
as COS (e,.g., COS-1 and COS-7) and CV-1 monkey cell
5 lines, 3T~i lines derived from Swiss, Balb-c or NIH
cells, Heha and L-929 mouse cells, and CHO, BHK or HaK
hamster cealls. Depending upon the host employed,
recombinant polypeptides produced in accordance herewith
will be g:Lycosylated with maxranalian or other eucaryotic
10 carbohydrates or may be non-glycosylated.
The preferred production method will vary
depending upon many factors and considerations; the
optimum production procedure for a given situation will
be apparent to those skilled in the art through minimal
15 experiment=ation. The resulting expression product may
then be purified! to near homogeneity using procedures
known in Lhe art.. A typical purification procedure for
procaryot:ic cell. production involves rupturing the cell
walls by high pressure or other means, centrifugation or
20 filtration to remove cellular debris followed by ion
exchange chromatography of supernatant or filtrate and,
finally, hydrophobic interaction chromatography. If the
analog is expressed in insoluble form, another
purification technique involves first solublizing the
25 inclusion bodiess containing the analogs followed by ion
exchange chromatography, then refolding of the protein,
and, finally, hydrophobic interaction chromatography.
Exemplary purification techniques include a method for
30
purifying a keratinocyte growth factor comprising: (a)
obtaining a solution comprising the KGF; (b) binding the
KGF from the so:Lution of part (a) to a cation exchange
resin; (c) eluting the RGF in an eluate solution from
35 the cation exchange resin; (d) either passing the eluate
solution from part (c) through an appropriate molecular
CA 02202075 1998-03-06
WO 96/11949 PCTI1895I00971
- 23 -
weight exclusion matrix or performing hydrophobic
interaction chromatography on the eluate solution of
part (c); and (e) recovering the KGF from the molecular
weight exclusion matrix or hydrophobic interaction
chromatography.
Of course, the analogs may be rapidly screened
to assess their physical properties. The Examples
section set forth various well-known stability assays,
although the specific assay used to test the analog is
not critical. Moreover, the level of biological
activity (e. g., receptor binding and/or affinity,
mitogenic, cell proliferative and/or in vivo activity)
may also be tested using a variety of assays, some of
which are set forth in the Examples section. Numerous
assays are well-known and can be used to quickly screen
the KGF analogs to determine whether or not they possess
acceptable biological activity. One such assay
specifically tests the KGF analogs for the ability to
bind to the KGF receptor (KGFR) by competing with
1251-KGF binding (Bottaro et a1. (1990), J. Biol. Chem.,
265:12767-12770; Ron et a1. (1993), J. Biol. Chem.,
268:2984-2988). An alternative method for assaying
KGFR/KGF analog interactions involves the use of
techniques such as real time biospecific interaction
analysis (BIA) (Felder et a1. (1993), Molecular &
Cellular Biology, 13:1449-1455). Additionally a
mitogenic assay can be utilized to test the ability of
the KGF analogs to stimulate DNA synthesis (Rubin et a1.
(1989), supra). Finally, cell proliferative assays can
be utilized to test the ability of the KGF analogs to
stimulate cell proliferation (Falco, et a1. (1988),
Oncogene, 2_:573-578). Using any of the aforementioned
assay systems, KGF analogs can be rapidly screened for
their biological activity.
In a preferred embodiment, the present
invention is directed to KGF analogs which retain the
CA 02202075 1998-03-06
WO 96/11949 PCTIIB95100971
- 24 -
full (i.e., at least substantially similar) in vitro
or in vivo biological activity to that of native KGF.
Exemplary KGF analogs with these properties, as
determined by one or more of the above assays,
are C(1,15)S, ~1V3/C(15)S, ~N3/C(15)-, ON8/C(15)S,
~1V8/C(15)-, ON15, ~N16, ON17, ON18, DI~T19, ON20, ON21,
ON22, ~I~T23, ~1V24 or O1V23/R(144)Q.
The KGF analogs may be further modified to
contain additional chemical moieties not normally a part
of the peptide. Such derivatized moieties may improve
the solubility, absorption, biological half life, and
the like of the KGF analog. The moieties may
alternatively eliminate or attenuate any undesirable
side effects of the protein and the like. Moieties
capable of mediating such effects are disclosed, for
example, in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th
ed., Mack Publishing Co., Easton, PA (1990). Covalent
modifications may be introduced into the molecule by
reacting targeted amino acid residues of the peptide
with an organic derivatizing agent that is capable of
reacting with selected side chains or terminal residues
(T. E. Creighton (1983), PROTEINS: STRUCTURE AND MOLECULE
PROPERTIES, W.H. Freeman & Co., San Francisco,
pp. 79-86). Polyethylene glycol ("PEG") is one such
chemical moiety which has been used in the preparation
of therapeutic protein products. For some proteins, the
attachment of polyethylene glycol has been shown to
protect against proteolysis, Sada, et a1.(1991), J.
Fermentation Bioengineering, 71:137-139 , and methods
for attachment of certain polyethylene glycol moieties
are available. ee U.S. Patent No. 4,179,337, Davis et
al., "Non-Immunogenic Polypeptides," issued December 18,
1979; and U.S. Patent No. 4,002,531, Royer, "Modifying
enzymes with Polyethylene Glycol and Product Produced
Thereby," issued January 11, 1977. For a review, see
Abuchowski et al., in Enzymes as Drugs. (Holcerberg and
CA 02202075 1998-03-06
WO 96111949 PCTI1895/00971
- 25 -
Roberts, (eds.) pp. 367-383 (1981)). For polyethylene
glycol, a variety of means have been used to attach the
polyethylene glycol molecules to the protein.
Generally, polyethylene glycol molecules are connected
to the protein via a reactive group found on the
protein. Amino groups, such as those on lysine residues
or at the N-terminus, are convenient for such
attachment. For example, Royer (U. S. Pat.
No. 4,002,531, above) states that reductive alkylation
was used for attachment of polyethylene glycol molecules
to an enzyme. EP 0 539 167, published April 28, 1993,
Wright, "Peg Imidates and Protein Derivates Thereof"
states that peptides and organic compounds with free
amino groups) are modified with an imidate derivative
of PEG or related water-soluble organic polymers. U.S.
Patent No. 4,904,584, Shaw, issued February 27, 1990,
relates to the modification of the number of lysine
residues in proteins for the attachment of polyethylene
glycol molecules via reactive amine groups.
In yet another embodiment, the present
invention is directed to a single-dose administration
unit of a medicinal formulation, which can be safely
administered parenterally or orally to treat a disease
in a warm-blooded animal (such as a human). Such
medicinal formulation may be in the form of a
lyophilized or otherwise dehydrated therapeutic or
diagnostic which can be reconstituted by the addition of
a physiologically acceptable solvent. The solvent may
be any media such as sterile water, physiological saline
solution, glucose solution or other aqueous
carbohydrates (e. g., polyols such as mannitol, xylitol
or glycerol) which is capable of dissolving the dried
composition, which is compatible with the selected
administration route and which does not negatively
interfere with the active principle and the
reconstitution stabilizers employed. In a specific
CA 02202075 1998-03-06
WO 96111949 PCT/IB95I00971
- 26 -
embodiment, the present invention is directed to a kit
for producing the single-dose administration unit. The
kit contains both a first container having a dried
protein and a second container having an aqueous
formulation comprising a reconstitution stabilizer. As
for the concentration of the protein in the solution,
the solution volume which is charged into each
container, and the capacity of the containers
(interrelated parameters which can be suitably modified,
depending upon the desired concentration of active
principle in the end-dosage unit), these may vary within
wide ranges well-known to skilled artisans.
KGF analogs according to the invention may be
useful as therapeutic and diagnostic agents and as
research reagents. Thus the KGF analogs may be used in
in vitro and/or in vivo diagnostic assays to quantify
the amount of KGF in a tissue or organ sample or to
determine and/or isolate cells which express KGFR
(Bottaro et a1. (1990), J. Biol. Chem., 265:12767-12770;
Ron et a1. (1993), J. Biol. Cherri., 268:2984-2988). In
assays of tissues or organs there will be less
radioactivity from l2sl-KGF analog binding to KGFR, as
compared to a standardized binding curve of l2sl-KGF
analog, due to unlabeled native KGF binding to KGFR.
Similarly, the use of llSI-KGF analog may be used to
detect the presence of KGFR in various cell types.
This invention also contemplates the use of a
KGF analog in the generation of antibodies made against
the peptide, which antibodies also bind to native KGF.
In this embodiment, the antibodies are monoclonal or
polyclonal in origin and are generated using a KGF
analog. The resulting antibodies bind preferentially to
native KGF, preferably when that protein is in its
native (biologically active) conformation. These
antibodies can be used for detection or purification of
the native KGF.
CA 02202075 1998-03-06
WO 96/11949 PCT/1895/00971
- 27 -
Moreover, the invention contemplates the use
of the KGF analogs in the discovery of high affinity or
low affinity KGF binding molecules having therapeutical
applications, for example, as a way for efficient KGF
delivery or as an inhibitor for KGF activity. The
thermal stability of the KGF analogs is important to
identify such binding molecules in physiological
conditions (i.e., at 37'C) since their affinity for KGF
could be strongly temperature-dependent and may be
unpredictable from the affinity observed at 4'C.
For in vivo uses, the KGF analogs may be
formulated with additives. Such additives include
buffers, carriers, stabilizers, excipients,
preservatives, tonicity adjusting agents, anti-oxidants
and the like (e.g., viscosity adjusting agents or
extenders). The selection of specific additives will
depend upon the storage form (i.e., liquid or
lyophilized) and the modes of administering the KGF
analog. Suitable formulations, known in the art, can be
found in REMINGTON'S PHARMACEUTICAL SCIENCES (latest
edition), Mack Publishing Company, Easton, PA.
The KGF analogs may be applied in
therapeutically effective amounts to tissues
specifically characterized by having damage to or
clinically insufficient numbers of non-fibroblast
epithelium cells. Areas in which KGF analogs may be
successfully administered include, but are not limited
to: the stimulation, proliferation and differentiation
of adnexal structures such as hair follicles, sweat
glands, and sebaceous glands in patients with burns and
other partial and full-thickness injuries; accelerated
reepithelialization of lesions caused by epidermolysis
bullosa, which is a defect in adherence of the epidermis
to the underlying dermis, resulting in frequent open,
painful blisters which can cause severe morbidity;
preventing chemotherapy-induced alopecia and treating
CA 02202075 1998-03-06
WO 96!11949 PCTIIB95/00971
- 28 -
male-pattern baldness, or the progressive loss of hair
in men and women; treating gastric and duodenal ulcers;
treating inflammatory bowel diseases, such a Crohn's
disease (affecting primarily the small intestine) and
ulcerative colitis (affecting primarily the large
bowel); preventing or reducing gut toxicity in radiation
and chemotherapy treatment regimes through treatment
(e.g., pretreatment and/or postreatment) to induce a
cytoprotective effect or regeneration or both;
stimulating the production of mucus throughout the
gastrointestinal tract; inducing the proliferation and
differentiation of type II pneumocytes, which may help
treat or prevent diseases such as hyaline membrane
disease (i.e., infant respiratory distress syndrome and
bronchopulmonary dysplasia) in premature infants;
stimulating the proliferation and differentiation of the
bronchiolar and/or alveolar epithelium with acute or
chronic lung damage or insufficiency due to inhalation
injuries (including high oxygen levels), emphysema, use
of lung damaging chemotherapeutics, ventilator trauma or
other lung damaging circumstances; increasing liver
function to treat or prevent hepatic cirrhosis,
fulminant liver failure, damage caused by acute viral
hepatitis and/or toxic insults to the liver; inducing
corneal cell regeneration, for example in the treatment
of corneal abrasion; inducing epithelial cell
regeneration to treat progressive gum disease; inducing
regeneration of tympanic epithelial cells to treat ear
drum damage and treating or preventing the onset of
diabetes mellitus or as an adjunct in the setting of
islet cell transplantation.
A patient in need of proliferation of non-
fibroblast epithelial cells will be administered an
effective amount of a KGF analog. An "effective amount"
is that amount of the KGF analog required to elicit the
desired response in the patient being treated and will,
CA 02202075 1998-03-06
WO 96/11949 PCT/1895100971
- 29 -
thus, generally be determined by the attending
_ physician. Factors influencing the amount of KGF analog
administered will include the age and general condition
of the patient, the disease being treated, etc. Typical
dosages will range from 0.001 mg/kg body weight to 500
mg/kg body weight.
The KGF analog may be safely administered
parenterally (e. g., via IV, IT, IM, SC, or IP routes),
orally or topically to warm-blooded animals (such as
humans). The KGF analog may be used once or
administered repeatedly, depending on the disease and
--- the condition of the patient. In some cases, the KGF
analog may be administered as an adjunct to other
therapy and also with other pharmaceutical preparations.
The following examples are included to more
fully illustrate the present invention. It is
understood that modifications can be made in the
procedures set forth, without departing from the spirit
of the invention.
EXAMPLES
Standard methods for many of the procedures
described in the following examples, or suitable
alternative procedures, are provided in widely
recognized manuals of molecular biology such as, for
example, Molecular Cloning, Second Edition, Sambrook et
al., Cold Spring Harbor Laboratory Press (1987) and
Current Protocols in Molecular Biology, Ausabel et al.,
Greene Publishing Associates/Wiley Interscience, New
York (1990).
EXAMPLE 1: Preparation of DNA Coding for KGF and KGF Analogs
The cloning of the full-length human KGF gene
(encoding a polypeptide with the sequence of native KGF)
CA 02202075 1998-03-06
WO 96/11949 PCT/1895100971
- 30 -
was carried out both by polymerase chain reaction (PCR)
of RNA from an animal cell and by PCR of chemically
synthesized (E. coli optimized codon) oligonucleotides
("OLIGOs"). Both procedures are described below:
PCR amplification using RNA isolated from
cells known to produce the polypeptide was performed.
Initially, cells from a human fibroblast cell line
AG1523A (obtained from Human Genetic Mutant Cell
Culture Repository Institute For Medical Research,
Camden, New Jersey) were disrupted with guanidium
thiocyanate, followed by extraction (according to the
method of Chomyzinski et al. (1987), Anal. Biochem.,
172:156). Using a standard reverse transcriptase
protocol for total RNA, the KGF cDNA was generated.
PCR (PCR#1) amplification of the KGF gene was carried
out using the KGF cDNA as template and primers OLIGO#1
and OLIGO#2 that encode DNA sequences immediately 5'
and 3' of the KGF gene [Model 9600 thermocycler
(Perkin-Elmer Cetus, Norwalk, CT); 28 cycles; each
cycle consisting of one minute at 94°C for
denaturation, two minutes at 60°C for annealing, and
three minutes at 72°C for elongation]. A small aliquot
of the PCR#1 product was then used as template for a
second KGF PCR (PCR#2) amplification identical to the
cycle conditions described above except for a 50°C
annealing temperature. For expression cloning of the
KGF gene, nested PCR primers were used to create
convenient restriction sites at both ends of the KGF
gene. OLIGO#3 and OLIGO#4 were used to modify the KGF
DNA product from PCR#2 to include Mlul and BamHI
restriction sites at the 5' and 3' ends of the gene,
respectively [PCR#3; 30 cycles; each cycle consisting
of one minute at 94°C for denaturation, two minutes at
60°C for annealing, and three minutes at 72°C for
elongation]. This DNA was subsequently cut with MIuI
and BamHI, phenol extracted, and ethanol precipitated.
CA 02202075 1998-03-06
WO 96111949 PCT/IB95100971
- 31 -
It was then resuspended and ligated (using T4 ligase)
into a pCFM1156 plasmid (Figure 2A) that contained a
"RSH" signal sequence to make construct RSH-KGF
(Figure 3).
The ligation products were transformed
(according to the method of Hanahan (1983), J. Mol.
Biol., 166:557) into E. coli strain FM5 (ATCC: 53911)
and plated onto LB+kanamycin at 28°C. Several
transformants were selected and grown in small liquid
cultures containing 20 ug/mL kanamvcin. The RSH-KGF
plasmid was isolated from the cells of each culture and
DNA sequenced. Because of an internal Ndel site in the
KGF gene, it was not possible to directly clone the
native gene sequence into the desired expression vector
with the bracketed restriction sites of Ndel and BamXI.
This was accomplished as a three-way ligation. Plasmid
RSH-KGF was cut with the unique restriction sites of
Bsml and Sstl, and a ~3 kbp DNA fragment (containing
the 3' end of the KGF gene) was isolated following
electrophoresis through a 1~ agarose gel. A PCR
(PCR#4) was carried out as described for PCR#3 except
for the substitution of OLIGO#5 for OLIGO#3. The PCR
DNA product was then cut with Ndel and Bsml and a 311
by DNA fragment was isolated following electrophoresis
through a 4~ agarose gel. The third piece of the
ligation is a 1.8 kbp DNA fragment of pCFM1156 cut with
Ndel and Sstl isolated following electrophoresis
through a 1~ agarose gel. Following ligation (T4
ligase), transformation, kanamycin selection and DNA
sequencing as described above, a clone was picked
containing the construct in Figure 4 and the plasmid
_. designated KGF. Because of an internal ribosomal
binding site that produced truncated products, the KGF
DNA sequence between the unique Kpnl and EcoRI sites
was replaced with chemically synthesized OLIGOs
CA 02202075 1998-03-06
WO 96111949 PCT/1895/00971
- 32 -
(OLIGO#6 through OLIGO#11) to minimize the use of the
internal start site (Figure 5).
OLIGO#1 (SEQ ID N0:7): 5'-CAATGACCTAGGAGTAACAATCAAC-3'
OLIGO#2 (SEQ ID N0:8): 5'-AAAACAAACATAAATGCACAAGTCCA-3'
OLIGO#3 (SEQ ID N0:9): 5'-ACAACGCGTGCAATGACATGACTCCA-3'
OLIGO#4 (SEQ ID NO:10):
5'-ACAGGATCCTATTAAGTTATTGCCATAGGAA-3'
OLIGO#5 (SEQ ID N0:11):
1O 5'-ACACATATGTGCAATGACATGACTCCA-3'
OLIGO#6 (SEQ ID N0:12):
--- 5'-CTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCC-3'
OLIGO#7 (SEQ ID N0:13):
5'-AAGAGATGAAAAACAACTACAATATTATGGAAATCCGTACTGTT-3'
OLIGO#8 (SEQ ID N0:14):
5'-GCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTG-3'
OLIGO#9 (SEQ ID N0:15):
5'-TCTTGGGTGCCCTTGACTTTGCCGCGTTTGTCGATACGCAGGTAC-3'
OLIGO#10 (SEQ ID N0:16):
5'-ACAGCAACAGTACGGATTTCCATAATATTGTAGTTGTTTTTCATC-3'
OLIGO#11 (SEQ ID N0:17):
5'-AATTCAGATTCAACACCTTTGATTGCAACGATACCA-3'
The OLIGOs were phosphorylated with T4
polynucleotide kinase and then heat denatured. The
single-stranded (ss) OLIGOs were then allowed to form a
ds DNA fragment by allowing the temperature to slowly
decrease to room temperature. T4 ligase was then used
to covalently link both the internal OLIGO sticky-ends
and the whole ds OLIGO fragment to the KGF plasmid cut
with Kpnl and EcoRI. The new plasmid was designated
KGF(dsd).
A completely E. coli codon-optimized KGF gene
was constructed by PCR amplification of chemically
synthesized OLIGOs #12 through 24.
CA 02202075 1998-03-06
WO 96/11949 PCTlIB95100971
- 33 -
OLIGO#12 (SEQ ID N0:18): 5'-AGTTTTGATCTAGAAGGAGG-3'
OLIGO#13 (SEQ ID N0:19): 5'-TCAAAACTGGATCCTATTAA-3'
OLIGO#14 (SEQ ID N0:20):
5'-AGTTTTGATCTAGAAGGAGGAATAACATATGTGCAACGACATG-
ACTCCGGAACAGATGGCTACCAACGTTAACTGCTCCAGCCCGGAACGT-3'
OLIGO#15 (SEQ ID N0:21):
5'-CACACCCGTAGCTACGACTACATGGAAGGTGGTGACATCCGT-
GTTCGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAA-3'
OLIGO#16 (SEQ ID N0:22):
5'-CGTGGTAAAGTTAAAGGTACCCAGGAAATGAAAAACAACTACAACATC-
ATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAA-3'
OLIGO#17 (SEQ ID N0:23):
5'-GGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACT-
GTACGCAAA.AAAAGAATGCAACGAAGACTGCAACTTCAAAGAA-3'
OLIGO#18 (SEQ ID N0:24):
5'-CTGATCCTGGAAAACCACTACAACACCTACGCATCTGCTAAATGGAC-
CCACAACGGTGGTGAAATGTTCGTTGCTCTGAACCAGAAAGGT-3'
OLIGO#19 (SEQ ID N0:25):
5'-ATCCCGGTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTC-
ACTTCCTGCCGATGGCAATCACTTAATAGGATCCAGTTTTGA-3'
OLIGO#20 (SEQ ID N0:26):5'-TACGGGTGTGACGTTCCGGG-3'
OLIGO#21 (SEQ ID N0:27):5'-CTTTACCACGTTTGTCGATA-3'
OLIGO#22 (SEQ ID N0:28):5'-ATTCAACACCTTTGATTGCA-3'
OLIGO#23 (SEQ ID N0:29):5'-CCAGGATCAGTTCTTTGAAG-3'
OLIGO#24 (SEQ ID N0:30):5'-GAACCGGGATACCTTTCTGG-3'
OLIGOs #l2 through 24 were designed so
that the entire DNA sequence encoding native KGF was
represented by OLIGOs from either the "Watson" or the
"Crick" strand and upon PCR amplification would produce
the desired double-stranded DNA sequence (Figure 6)
[PCR#5, Model 9600 therrnocycler, Perkin-Elmer Cetus]; 21
cycles, each cycle consisting of 31 seconds at 94°C for
denaturation, 31 seconds at 50°C for annealing, and 31
seconds at 73°C for elongation; following the 21 cycles
the PCR was finished with a final elongation step of 7
CA 02202075 1998-03-06
WO 96/11949 PCT/IB95/00971
- 34 -
minutes]. After PCR amplification, the DNA fragment was
cut with Xbal and BamHI and the 521 by fragment ligated
into the expression plasmid pCFM1156 cut with the same
enzymes. PCR#5 utilized the outside primers (100
pmoles/100 ~.l rxn) OLIGO#12 and OLIGO#13 and 1 x.1/100 ~,1
rxn of a KGF template derived by ligation (by T4 ligase)
of OLIGO#14 through OLIGO#19 (OLIGO#15 through OLIGO#18
were phosphorylated with T4 polynucleotide kinase) using
OLIGO#20 through OLIGO#24 as band-aid oligos (Jayaraman
et a/. (1992), Biotechniques, 12:392) for the ligation.
The final construct was designated KGF
(codon optimized).
All of the KGF analogs described herein are
composed in part from DNA sequences found in KGF(dsd) or
KGF(codon optimized), or a combination of the two. The
sequences are further modified by the insertion into
convenient restriction sites of DNA sequences that
encode the particular KGF analog amino acids made
utilizing one or more of the above-described techniques
for DNA fragment synthesis. Any of the analogs can be
generated in their entirety by the above described
techniques. However, as a part of the general OLIGO
design optimized E. coli codons were used where
appropriate, although the presence of E. coli optimized
codons in part or in toto of any of the genes where
examined did not significantly increase the yield of
protein that could be obtained from cultured bacterial
cells. Figures 7 to 24 and 37 to 50 set forth by
convenient example particular KGF analog nucleotide and
amino acid sequence constructions: C(1,15)S (Figure 7);
~1~T3/C(15)S (Figure 8); ON3/C(15)- (Figure 9); ~1V8/C(15)S
(Figure 10); ~1V8/C(15)- (Figure 11); AN15 (Figure 12);
~I~T16 (Figure 13); ~N17 (Figure 14); ON18 (Figure 15);
ON19 (Figure 16); ~N20 (Figure 17); ~I~T21 (Figure 18); -
4N22 (Figure 19); ~N23 (Figure 20); ON24 (Figure 21);
C(1,15)S/R(144)E (Figure 22); C(1,15)S/R(144)Q
CA 02202075 2000-07-26
WO 96111949 p~~9~pp971
- 35 -
(Figure 23); aN23/R(:144)Q (Figure 24); C(1,15,40)S
(Figure 36); C(1,15,:102)S (Figure 37); C(1,15,102,106)S
(Figure 38); DN23/N(:L37)E (Figure 39); ~N23/K(139)E
(Figure 40); ~N23/K(:L39)Q (Figure 41); ON23/R(144)A
(Figure 42); AN23/R(144)E (Figure 43); ~,N23/R(144)L
(Figure 44); AN23/K(:L47)E (Figure 45); ON23/K(147)Q
(Figure 46); AN23/K(153)E (Figure 47); ON23/K(153}Q
(Figure 48) and aN23/Q(152)E/K(153)E (Figure 49). All
the KGF analog consts-uctions described herein were DNA
sequence confirmed.
EXAMPLE 2: Production in E. coli
A. Expression of F;GF Analogs
Three different expression plasmids were
utilized in the cloning of the KGF analog genes. They
were pCFM1156 (ATCC# 69702}, pCFM1656 (ATCC# 69576), and
pCFM3102 (Figures 2A, 2B and 2C, respectively). The
plasmid p3102 can beg derived from the plasmid pCFM1656
by making a series .of site-directed base changes with
PCR overlapping ol.ic~o mutagenesis . Starting with the
EglII site (pC:fMl656 plasmid by # 180) immediately 5' to
the plasmid replication promoter, Pcopg, and proceeding
toward the plasmid replication genes, the base pair
changes are as follows:
CA 02202075 1998-03-06
WO 96/11949 PCTI1895100971
- 36 -
pCFM1656 by by in pCFM1656 by changed to in pCFM3102
#
# 204 T/A C/G
# 428 A/T G/C _ w
# 509 G/C A/T
# 617 - - insert two G/C by
# 677 G/C T/A
# 978 T/A C/G
# 992 G/C A/T
# 1002 A/T C/G
# 1005 C/G T/A
# 1026 A/T T/A
# 1045 C/G T/A
# 1176 G/C T/A
# 1464 G/C T/A
# 2026 G/C by deletion
# 2186 C/G T/A
# 2479 A/T T/A
# 2498-2501 A T GT A
TCAC CAGT
# 2641-2647 TCCGAGC by deletion
AGGCTCG
# 3441 G/C A/T
# 3452 G/C A/T
# 3649 A/T T/A
# 4556 -- insert bps
(SEQ ID N0:67) 5'-GAGCTCACTAGTGTCGACCTGCAG-3'
(SEQ ID N0:68) 3'-CTCGAGTGATCACAGCTGGACGTC-5'
As seen above, pCFM1156, pCFM1656 and pCFM3102
are very similar to each other and contain many of the
same restriction sites. The plasmids were chosen by
convenience, and the vector DNA components can be easily
exchanged for purposes of new constructs. The host used
for all cloning was E. coli strain FM5 (ATCC: 53911) and
the transformations were carried out (according to the
method of Hanahan (1983), supra) or by electroelution
with a Gene Pulser'~" transfection apparatus (BioRad
Laboratories, Inc., Hercules, CA) according to the
manufacturer's instructions.
Initially, a small, freshly cultured inoculum
of the desired recombinant E. coli clone harboring the
CA 02202075 1998-03-06
WO 96111949 PCTlIB95/00971
- 37 -
desired construct on one of the three pCFM vectors was
_ started by transferring 0.1 mL of a frozen glycerol
stock of the appropriate strain into a 2 L flask
containing 500 mL of Luria broth. The culture was
shaken at 30'C for 16 hours, after which the culture was
transferred to a 15 L fermentor containing 8 L of
sterile batch medium (Tsai, et a1. (1987), J. Industrial
Microbiol., 2_:181-187).
Feed batch fermentation starts with the
feeding of Feed # 1 medium (Tsai, et a1. (1987),
supra). When the OD600 reached 35, expression of the
desired KGF analog was induced by rapidly raising the
culture temperature to 37'C for two hours then up to
42'C to denature the CI repressor. The addition of Feed
1 was discontinued in favor of Feed 2, the addition rate
of which was initiated at 300 mL/hr. Feed 2 comprised
175 g/L trypticase-peptone, 87.5 g/L yeast extract, and
260 g/L glucose. After one hour at 42'C, the culture
temperature was decreased to 36'C, where this
temperature was then maintained for another 6 hours.
The fermentation was then halted and the cells
were harvested by centrifugation into plastic bags
placed within 1 L centrifuge bottles. The cells were
pelleted by centrifugation at 400 rpm for 60 minutes,
after which the supernatants were removed and the cell
paste frozen at -90'C.
Following expression of the various KGF
analogs in E. coli, native KGF, C(1,15)S,
C(1,15)S/R(144)E, C(1,15)S/R(144)Q, ON15, ~N23, and
. 30 ON23/R(144)Q proteins were purified using the following
procedure. Cell paste from a high cell density
fermentation was suspended at 4'C in 0.2 M NaCl, 20 mM
NaP04, pH 7.5 as a 10-20~ solution (weight per volume)
using a suitable high shear mixer. The suspended cells
were then lysed by passing the solution through a
homogenizer (APV Gaulin, Inc., Everett, MA) three times.
CA 02202075 1998-03-06
WO 96111949 PCT/IB95100971
- 38 -
The outflowing homogenate was cooled to 4-8'C by using a
suitable heat exchanger. Debris was then removed by
centrifuging the lysate in a J-6B~ centrifuge (Beckman
Instruments, Inc., Brea, CA) equipped with a JS 4.2
rotor at 4,200 rpm for 30-60 min. at 4'C. Supernatants
were then carefully decanted and loaded onto a
previously prepared 450 mL (5 cm x 23 cm) column of S-
Sepharose Fast Flov,fM resin (Pharmacia, Piscataway, NJ)
equilibrated with 0.2 M NaCl, 20 mM NaP04, pH 7.5 at
4'C. Next, the column was washed with five column
volumes (2250 mL) of 0.4 M NaCl, 20 mM NaP04, pH 7.5 at
4'C. The desired protein was eluted by washing the
column with 5 L of 0.5 M NaCl, 20 mM NaP04, pH 7.5.
50 mL fractions were collected and the A28o of the
effluent was continuously monitored. Fractions
identified by A2go as containing eluted material were
then analyzed by SDS-PAGE through 14~ gels to confirm
the presence of the desired polypeptide.
Those fractions containing proteins of
interest were then pooled, followed by the addition of
an equal volume of distilled water. The diluted sample
was then loaded onto a previously prepared a 450 mL
(5 cm x 23 cm) column of S-Sepharose Fast Flog-
equilibrated with 0.4 M NaCl, 20 mM Nat~04, pH 6.8 at=
4'C. The column was washed with 2250 mL of 0.4 M NaCl,
20 mM NaP04, pH 6.8 and the protein eluted using a 20
column volume linear gradient ranging from 0.4 M NaCl,
20 mM NaP04, pH 6.8 to 0.6 M NaCl, 20 mM NaP04, pH 6.8.
Again, 50 mL fractions were collected under constant A2so
monitoring of the effluent. Those fractions containing
the protein (determined by 14~ SDS-PAGE) were then
pooled, followed by concentration through a YM-10
membrane (10,000 molecular weight cutoff) in a 350cc
stirring cell (Amicon, Inc. Mayberry, MA) to a volume of
30-40 mL.
CA 02202075 1998-03-06
WO 96!11949 PCT/1895100971
- 39 -
The concentrate was then loaded onto a
previously generated 1,300 mL (4.4 cm x 85 cm) column of
Superdex-75T1"' resin (Pharmacia) equilibrated in column
buffer comprising 1X PBS (Dulbecco's Phosphate Buffered
Saline, "D-PBS", calcium and magnesium-free) or 0.15 M
NaCl, 20 mM NaP04, pH 7Ø After allowing the sample to
run into the column, the protein was eluted from the gel
filtration matrix using column buffer. Thereafter,
mL fractions were recovered and those containing the
10 analog (determined by 14~ SDS-PAGE) were pooled.
Typically, the protein concentration was about 5-10
---- mg/mL in the resultant pool. All of the above
procedures were performed at 4-8'C, unless otherwise
specified.
An alternative purification procedure was used
to purify native KGF, C(1,15)S and ~N23. The procedure
involves the following steps, and unless otherwise
specified, all procedures, solutions and materials were
conducted at 23 + 5'C.
Upon completion of the production phase of a
bacterial fermentation, the cell culture was cooled to
4-8'C and the cells harvested by centrifugation or a
similar process. On the basis of the expected yield of
protein per unit weight of cell paste and the amount of
purified protein required, an appropriate amount of cell
paste, by weight, was suspended in a mild buffer
solution of 20 mM NaP04, 0.2 M NaCl, pH 7.5, weighing
about five times that of the cell paste to be suspended.
The cells were dispersed to a homogeneous solution using
a high shear mixer. The temperature of the cell paste
dispersion was maintained at 4-8'C during
homogenization.
The cells were then lysed by pressure, for
example by passing the cell paste dispersion twice
through an appropriately-sized cell homogenizer. The
homogenate was kept chilled at 5 ~ 3°C. To clarify the
CA 02202075 1998-03-06
WO 96111949 PCT/IB95/00971
- 40 -
cell lysate, a previously prepared depth filter housing
(Cuno, Inc., Meriden, CT) equipped with a filter having
an appropriate amount of filter surface area,
equilibrated with a suitable volume of 0.2 M NaCl, 20 mM _
NaP04, pH 7.5, was employed. The equilibration and
clarification were performed at 5 ~ 3'C. Prior to
clarification, an appropriate amount of a suitable
filter aid was used to pre-coat the filter and be
thoroughly mixed with the cell lysate, after which the
lysate was clarified by passing the solution through the
filter apparatus. The filter was washed with 0.2 M
NaCl, 20 mM NaP04, pH 7.5. The filtrate and any
subsequent wash were collected in a chilled container of
suitable capacity, all the while being maintained at
less than 10'C.
Following clarification, the lysate was then
passed through a previously prepared a column of
SP-Sepharose Fast Flow containing at least 1 mL of resin
per 2 g of cell paste. The column of SP-Sepharose Fast
Flow was equilibrated with cold (5 ~ 3'C), 0.2 M NaCl,
20 mM NaP04, pH 7.5. The temperature of the column was
maintained at less than 10'C. The clarified lysate
(5 ~ 3'C) was then loaded onto the ion exchange column,
with the absorbance at 280 nm (A2gp) of eluate being
continuously monitored. After sample loading, the
column was washed with cold 0.2 M NaCl, 20 mM NaP04, pH
7.5, followed by washing with 0.3 M NaCl, 20 mM NaP04,
pH 7.5 at 23 ~ 5'C.
To elute the desired protein, a linear
gradient ranging from 0.2-1 M NaCl, 20 mM NaP04, pH 7.5
was used. Bulk product was collected in several
fractions on the basis of the A28p of the eluate.
Following elution, these fractions were pooled and the
volume noted.
To oxidize free sulfhydryl groups, an
oxidation step was performed. For proteins with altered
CA 02202075 2000-07-26
WO 96/11949 PCT/1895100971
- 41 -
cysteine patterns, as compared to native KGF, an
oxidizing agent (e.g., cystamine dihydrochloride or
another appropriate oxidizing agent, for instance,
cystine, oxidized glutathione or divalent copper) was
added to a final concentration of 1-20 mM and the pH was
adjusted to 7-9.5, with a pH of 9.0 ~ 0.3 being
preferred when. cystarnine dihydrochloride was used. The
oxidation was conducted at 10-30'C for an appropriate
period. For the native RGF protein, oxidation was
accomplished h~y adding an appropriate amount of (NH4)2SOq
such as 1-2 M (NH4)zSOq, adjusting the pH to 7.5 ~ 0.5,
and holding the temperature at 23 ~ 5'C for an
appropriate period..
AftE:r oxidation, the pH of the solution was
adjusted to between i5.5 and 9.5. If necessary, solid
(NHq)2SOq was added t.o the solution to a final
concentration of 2 M. To remove particulates, the
solution was passed through appropriate clarification
filters.
The filtered, oxidized product was then
subjected to hydrophobic interaction chromatography
(HIC). The HIC matr:ice was Butyl-650M Toyopearh" resin
(Tosohaas, Inc., Moni~gomeryville, PA). The protein-
containing solution was loaded onto the column, which
had been previously equilibrated with 2 M (NHq)ZS04, 0.15
M NaCl, 20 mM :NaPOq, pH 7Ø After sample loading, the
column was washed with 2 M (NHq)2SOq, 0.15 M NaCl, 20 mM
NaPOq, pH 7Ø The desired protein was then eluted
using a decreasing linear (NH4)2SOq gradient ranging from
2-0 M developed in 0..15 M NaCl, 20 mM NaP04, pH 7Ø
When the desired protein began to elute, as indicated by
an increase in the A;;ep of the eluate, fractions were
collected. Aliquots of each fraction were then analyzed
by SDS-PAGE. 'Those i:ractions containing the desired
protein were then pooled, thoroughly mixed, and the
CA 02202075 1998-03-06
WO 96111949 PCT/IB95100971
- 42 -
volume of the pool determined, as was the concentration
of the protein therein.
The pooled HIC protein-containing eluate was
then concentrated and the elution buffer exchanged.
Typically, proteins were concentrated to 5.0-10.0
mg/mL. Ultrafiltration was conducted using an
ultrafiltration system equipped with a PTGC PelliconTM
cassette system (Millipore, Inc., Bedford, MA) with an
appropriately sized cut-off membrane
After concentration, the sample was
diafiltered against an appropriate buffer. The
retentate from the concentration step was diafiltered
against 0.15 M NaCl, 20 mM NaP04, pH 7.0 until the
conductivity of the retentate was within 5~ of the
conductivity of the 0.15 M NaCl, 20 mM NaP04, pH 7.0
solution.
In addition, to remove precipitates and
bacterial endotoxin that might be present, the
concentrated diafiltered protein-containing sample was
passed through a 0.1 Eun PosidyneT~"' filter (Pall, Inc. ,
Cortland, NY). After determining the protein
concentration of the solution and on the basis of the
desired concentration of the final bulk product, the
solution was diluted with 0.15 M NaCl, 20 mM sodium
phosphate, pH 7.0, to the desired final concentration.
A final aseptic filtration through a 0.22 E.im filter was
then performed as the final bulk product was transferred
to a pyrogen-free container for storage (at about 5'C)
for further formulation.
B. Analysis '
Analysis was conducted using E. coli-derived,
native KGF; C(1,15)S; C(1,15)S/R(144)Q; ON15; ~N23 and
~N23/R(144)Q.
CA 02202075 2000-07-26
WO 96/11949 p~'/~g~/ppg71
- 43 -
The polypeptides were compared by their
storage stability, thermal unfolding transition
temperatures (Tm), and stability in a broad range of pH
conditions.
Fig~ire 25 compares native KGF and C(1,15)S
when stored in 20 mM NaP04 , 0.15 M NaCl, pH 7.0
at 37'C for 27 hrs. C(1,15)S showed a significantly
increased amoLint of soluble protein relative to native
KGF.
Fig~sre 26 compares the stability of native KGF, 0N15
(data not shown) and C(1,15)S in PBS and in 50 mM NaP04, 0.15 M
NaCl, pH 7.0, when stored at 37'C for 18 hrs. The
recovery of soluble protein is much higher in high
phosphate thar.~ in PB;S ~ ~N15 as well as
C(1,15)S showed significantly enhanced stability, as
compared with native KGF. AN15 and C(1,15)S also gave
~100~ recovery in high phosphate, as expected from the
result of native RGF.
However, a single preliminary comparative
example of storage stability was conducted between
C(1,15,40)S, and C(40)S (which is encoded by bases 201
to 684 of SEQ ID NO::1, except that Ser4~ is encoded by
AGA); and between C(:1,15,102), and C(102)S (which is
CA 02202075 2000-07-26
WO 96111949 PCT/1895100971
- 44 -
encoded by bases 201 to 684 of SEQ ID NO:1, except that
Serlo2 is encoded by AGG). The results (not shown)
indicated a~ decreased stability (i.e., less soluble
protein after being stored at 37° C). However, the
5 amount of =;olub:le, correctly folded C(1,15,40)S protein
which was purified from the culture medium was greater
than that of C(40)S, suggesting that C(1,15,40)S may in
fact be move stable and that the results from the
comparatives example are inconclusive. The present
10 invention preferably includes a KGF analog having other
than substitutions at Cys40, Cys102~ Cyslo6 ~d more
preferably excludes C(1,15,40)S, C(1,15,102)S and
C(1,15,40,~.02,106)
The abilit~,r of native KGF, C(1,15)S, ~N23, C(1,15)S/R(144)E,
15 C(1,15)S/R(144)Q and ~N23/R(144)Q to prevent aggregation at
elevated tf=mperat~ures was also examined. Samples containing
0.5 mg/mL of protein were prepared in D-PBS. 0.5 mL of each
sample was aliquoted into 3 cc type-1 glass vials. The
vials were sealed, with rubber stoppers and 13 mm flip-
20 off alumintun seals were crimped on. These vials Were
then placed in a 37°C incubator. At predetermined time
intervals, vials were withdrawn and analyzed for the
loss of soluble protein. Visible precipitates were
removed by centrifuging 250 ~L of each sample through a
25 0.22 ~m Spin-X°"falter unit (Costar, Cambridge, MA).
Soluble protein in the filtered solutions was subsequently
analyzed by size exclusion HPLC. The amount of soluble
protein was determined by integrating the HPLC peak area and
plotting the result as a function of incubation time at 37°C.
30 The results for native KGF, C(1,15)S, C(1,15)S/R(144)E and
C(1,15)S/R(144)Q (the data for ~N23 and pN23/R(144)Q are not
shown) are shown in Figure 26.
The half-.lives for the loss of soluble, monomeric
protein were then estimated from these kinetic curves. Table
35 1 shows the ha:Lf-life for remaining soluble KGF upon storage
at 37°C for the:s~= proteins.
CA 02202075 2000-07-26
WO 96/11949 PCT/IB95I00971
- 45 -
Table 1
Half-life for the Loss of Soluble, Monomeric Proteins
Protein t1/2 da
native KGF 0.6
~N23 1.1
C(1,15)S 1.2
C(1,I5)S/R(144)Q 13.3
dI~T23 /R144Q 22 . 3
C(1 15 S/R 144iE 38.0
As seen in Table 1, above, and Figure 27, the
native KGF ag!~regated the most rapidly, with a
solubility half-lifer of 0.6 days. C(1,15)S/R(144)Q,
~N23/R(144)Q ;end C(1.,15)S/R(144)E showed substantial
increases in the solubility half-life to 13.3, 22.3 and
38 days, resp~~ctivel.y.
Thermal unfolding was monitored by circular
dichroism (CD) at 230 nm using a J-720
spectropolarimeter (Jasco, Inc., Easton, MD) equipped
with a PTC-343 Pelti.er-type temperature control system.
For CD analysis, separate samples containing 0.1 mg/mL
of the polypeptide t.o be analyzed were prepared in D-PBS
(Life Technologies, Inc., Grand Island, NY). For each
sample, about 2.5 mL, was loaded into a 10 mm path length
rectangular Suprasiln' quartz (Heraeus Quarzschmelze,
GmbH, Hanau, c;ermany) fluorescent cell (Hellma Cells,
Inc., Jamaica, NY). The cell was then placed into the
Peltier-type ~~emperature control system in the
spectropolarimeter. Thermal unfolding was carried out
at a rate of !50°C/hr. Changes in ellipticity were
monitored at 230 nm to indicate unfolding. The Tm of
each sample was estimated by identifying a temperature
CA 02202075 1998-03-06
WO 96111949 PGTI1895100971
- 46 -
at which 50~ of protein molecules in the solution were
unfolded (Biophysical Chemistry, Cantor and Schimmel
(eds), W.H. Freeman and Co. San Francisco (1980). The
estimated Tm for each of the three proteins is listed in
Table 2.
Table 2
Estimated Meltina Temperatures
Protein Tm ( C )
native KGF 54.0
~1V15 5 5 . 0
C(1,15)S 55.0
ON23 56.0
C(1,15)S/R(144)Q 62.5
QN23/R144Q 63.0
C(1,15)S/R(144)E 63.5
As these results show, C(1,15)S and ~N15 have
a 1°C increase in the Tm as compared with native KGF.
The O1V23 has an additional degree increase in Tm.
However, the substitution of R144Q to C(1,15)S/R(144)Q
or ~I~T23 adds a greater than 6°C increase in Tm and more
than 7°C as compared with native KGF. Moreover,
C(1,15)S/R(144)E is greater than 9°C more stable than
native KGF.
The acid stabilities of C(1,15)S/R(144)Q and t
C(1,15)S/R(144)E were also compared to that of native
KGF, by adjusting D-PBS to different pH values by adding ,
concentrated HCl or NaOH. Approximately 2.35 mL of
D-PBS at different pH values was mixed with 100 ~.L of
2.45 mg/mL KGF protein in a quartz cell. These samples
CA 02202075 2000-07-26
WO 96/11949 PCTIIB95/00971
_ 47 -
were thermall~,r unfolded at a rate of 50°C/hr and monitored by
CD at 230 nm. Figure 28 shows the Tm as a function of pH for
native KGF, C(1,15)~~, C(1,15)S/R(144)Q and C(1,15)S/R(144)E.
In the pH range tested, the C(1,15)S, C(1,15)S/R(144)Q and
C(1,15)S/R(14~~)E a.lHrays have a higher Tm than the native KGF.
In vitro Bioloqica,~", Activitv
In iitro m.itogenic activity of C(1,15)S, ~N15,
AN23, AN23/R(144)Q, C:(1,15)S/R(144)Q and
C(1,15)S/R(144)E was also determined as a function of
protein concentration and the half-maximal
concentrations by measurement of [3H]-thymidine uptake
by Balb/I~C cells (acc:ording to the methods of Rubin et
a1. (1989), su,pra). Generally, the concentrations of
each of the RG:P analogs relative to a known standard
native KGF was determined using an in vitro biological
assay. Each KGF analog was then diluted and assayed for
biological activity using a Balb/l~t mitogenic assay.
The samples we:ce first diluted in a bioassay medium
consisting of !50% cusstomer-made Eagle's MEN/, 50%
customer-made ~'I2, 5 ~1g/ml transferrin, 5 ng/ml sodium
selenite, 0.0005% HSA and 0.005% Tween 20. KGF samples
were then added into Falcon PrimeriaT'" 96-well plates
seeded with Ba:Lb/l4FC. cells . Incorporation of [ 3H] -
Thymidine during DNA synthesis was measured and
converted to input native KGF concentration by
comparison to a native RGF standard curve. The results
are presented in Figures 29 to 34. As seen in the Figures,
the tested KGF analogs described in Figures 28 to 33 have
comparable activity to native KGF.
CA 02202075 2000-07-26
WO 96J11949 PCTJIB95I00971
- 48 -
ale 3: Production in Mammalian Cell Culture
This Example describes the expression,
isolation,, and characterization of two biologically
5 active recombinant KGF (rKGF) forms produced in a
mammalian expression system.
The htunan KGF gene was isolated by PCR
amplificat=ion of cDNA made from normal dermal human
fibroblast cells (Clonetec, Inc., San Diego, CA).
10 Following the making of cDNA by reverse transcriptase,
PCR was u:~ed to amplify the KGF gene. OLIGO#25 and
OLIGO#26 ~Nere used to amplify the gene out of the cDNA,
and OLIG0;~27 and OLIGO#28 were used to place HindIII and
EglII restriction sites at the fragment ends by a second
15 PCR ampli:Eication, as set forth in Figures 1A and 1B.
OLIG0~125 (SEQ I1) N0:69): 5'-CAATCTACAATTCACAGA-3'
OLIGO~26 (SEQ I1) N0:70): 5'-TTAAGTTATTGCCATAGG-3'
OLIG0~127 (SEQ I1) N0:71): 5'-AACAAAGCTTCTACAATTCACAGATAGGA-3'
20 OLIGO#28 (SEQ I1) N0:72): 5'-AACAAGATCTTAAGTTATTGCCATAGG-3'
Following cloning and DNA sequence
confirmation, the KGF gene DNA was then used.
Amplification was effected using OLIGO#29 and OLIGO#30.
25
OLIGO#29 (SEQ IlJ N0:73)
!~'-CGGTCTAGACCACCATGCACAAATGGATACTGACATGG-3'
OLIGO#30 (SEQ ID N0:74):
'S'-GCCGTCGACCTATTAAGTTATTGCCATAGGAAG-3'
30
_ The sense primer, OLIGO#29, included an XbaI
site and .a consensus Kozak translation sequence (5'-
CCACC-3') upstream of the start codon, ATG. The
antisense primex-, OLIGO#30, included a SalI cloning site
35 and an additional stop codon. After 18 cycles of PCR
amplification (30 sec. denaturation at 94'C, 40 sec.
CA 02202075 1998-03-06
WO 96/11949 PCT/1895100971
- 49 -
annealing at 55'C, and 40 sec. elongation at 72'C), the
product was digested with XbaI and SalI and ligated with
a similarly digested DNA of pDSRa2 (according to the
methods of Bourdrel et a1. (1993), Protein Exp. &
Purif., 4:130-140 and Lu et a1. (1992), Arch. Biochem.
Biophys., 298:150-158). This resulted in plasmid
KGF/pDSRa2 which placed the human KGF gene between the
SV40 early promoter and the oc-FSH polyadenylation
sequences. Two clones were picked and DNA sequence
analysis confirmed construction of the desired vector.
Two micrograms of KGF/pDSRa2 DNA were then
linearized with PvuI. Chinese hamster ovary (CHO)
cells, seeded the day before at 0.8 x 106 cells/60 mm
culture dish, were then transfected with the treated DNA
using a standard calcium phosphate precipitation method
(Bourdrel et al., supra). Two weeks later, individual
colonies were picked and transferred into 24-well
plates. The conditioned media was considered serum free
when the cells reached confluency and aliquots thereof
were analyzed by Western blotting using a polyclonal
rabbit antiserum reactive against E. coli-expressed
human KGF:
Westerns were performed by running samples
through 12.5 (w/v) SDS polyacrylamide gels, followed by
electroblotting for 1 hr. at 400 mA onto nitrocellulose
membranes using a semidry transfer apparatus (Hoefer
Scientific Instruments, San Francisco, CA). 20 mM Tris,
150 mM glycine, 20~ methanol served as the transfer
buffer. The nitrocellulose sheets were blocked by
incubation with 10~ normal goat serum in PBS. Rabbit
anti-serum raised against E. coli-derived KGF was used
as primary antibody. For use, it was diluted 1/10,000
in 1~ normal goat serum in PBS and incubated with the
blocked nitrocellulose sheets for 12 hr. at room
temperature, after which excess antibody was removed by
three 30 min. washes in PBS. The nitrocellulose
CA 02202075 1998-03-06
WO 96/11949 PCT/IB95100971
- 50 -
membranes were then incubated in 100 mL of 1~ normal
goat serum in PBS containing Vectastain~ biotinylated ~,
goat anti-rabbit IgG (secondary antibody, Vector Labs,
Burlingame, CA) for 30 minutes at room temperature.
After three 10-minute washes in PBS, a 30-minute room
temperature incubation was performed in a 100 mL
solution of 1~ normal goat serum containing streptavidin
and biotinylated peroxidase, prepared according to
manufacturer's directions (Vector Labs). Following
three washes in PBS, KGF cross-reactive material was
visualized by incubation in a mixture of 60 ~.L of 30~
--- (w/v) H202 in 100 mL of PBS and 50 mg of 4 chloronapthol
in 20 mL of methanol. The reaction was stopped by
rinsing in water after 10 minutes.
Analysis of the blots revealed that the KGF-
specific antibody associated with three distinct protein
bands, two being closely related with molecular weights
of about 25-29 kDa and one with an estimated molecular
weight of about 17 kDa, as compared to the expected
molecular weight of approximately 18.8 of the 163
amino acid mature protein. Additionally, several
high-expressing clones secreting more than 2.0 mg of
rKGF per liter, as judged by Western analysis, were
selected and expanded into roller bottles (according to
the method of Lu et al., supra) to generate large
volumes of serum-free conditioned medium for
purification of KGF by cationic exchange chromatography
and gel filtration, as set forth below.
KGF from 3 L of serum-free conditioned medium
was purified applying the medium directly to a cation
exchange column (5 x 24 cm) packed with 450 mL of
sulfoethyl a column of S-Sepharose Fast Flow (Pharmacia)
pre-equilibrated with 20 mM sodium phosphate, pH 7.5.
After washing with five column volumes of 20 mM sodium
phosphate, 0.2 M NaCl, pH 7.5, rKGF was eluted using a
20-column volume linear gradient of 0.2 to 1.0 M NaCl in
CA 02202075 1998-03-06
WO 96/11949 PCT/>895100971
- 51 -
20 mM sodium phosphate, pH 7.5. 50 mL fractions were
collected with continuous AZgp monitoring. KGF protein
was detected by analyzing aliquots of each fraction by
SDS-PAGE. SDS-PAGE was performed on an electrophoresis
system (Novex, San Diego, CA) using precast 14~ Tris-
glycine precast gels (according to the method of Laemmli
(1970) Nature, 227:680-685). Samples were mixed with
non-reducing SDS sample buffer without heating before
loading. The proteins were detected by either Coomassie
blue or silver staining. Two late-eluting peaks were
seen to contain protein bands corresponding to the 25-29
kDa and 17 kDa bands detected by Western blot. The
fractions containing each of these peaks were separately
concentrated to a volume of less than 1.0 mL and
subjected to gel filtration.
The gel filtrations employed columns of
Superdex-75TH' resin (HR 10/30, Pharmacia) pre-
equilibrated with PBS, pH 7.2, and calibrated with the
following known molecular weight standards (BioRad, San
Francisco, CA): thyroglobulin (670 kDa), g-globulin
(158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and
vitamin B-12 (1.4 kDa). These purification steps
resulted in an approximate 2000-fold purification of
rKGF, specifically including a 17 kDa and a 30 kDa
material, as estimated by silver staining.
In the instance of the higher molecular weight
material, rKGF eluted as a major symmetrical peak
(by A28p) which was called KGF-a. Upon SDS-PAGE analysis
of a lesser amount of this material, 3 ~g/lane versus 6
ug/lane, two bands with a 1-2 kDa molecular weight
difference were resolved. In the instance of the lower
molecular weight material, termed KGF-b, gel filtration
resulted in a protein preparation having the expected
mobility. For both KGF-a and KGF-b, the overall yield
after purification was approximately 30-40~.
CA 02202075 1998-03-06
WO 96111949 PCTIIB95100971
- 52 -
Amino acid sequences from KGF-a and KGF-b were
also analyzed. These analyses were performed on an
automatic sequences (Model 477A or 470A, Applied
Biosystems, Inc., Foster City, CA) equipped with a Model
120A on-line PTH-amino acid analyzer and a Model 900A
data collection system (according to the method of Lu et
a1. (1991), J. Biol. Chem.,266:8102-8107). Edman
sequence analysis of KGF-a revealed a major N-terminal
sequence of X1-N-D-M-T-P-E-Q-M-A-T-N-V-X2-X3-S- [SEQ ID
N0:75]. A minor sequence starting from the third N-
terminal amino acid, aspartic acid, was also present in
1.6~ of the total sequenceable protein. X1, X2, and X3
were the unassigned due to the absence of
phenylthiohydantoinyl (PHT) amino acid signals during
sequence analysis. An N-terminal amino acid sequence of
KGF predicted from cDNA sequence indicates that X1 and X3
are Cys residues and X2 is asparagine. The absence of X1
and X3 indicates that these~cysteines may form disulfide
bridges. On the basis of the consensus N-linked
glycosylation sequence Asn-X-Ser, the absence of the
predicted Asn residue corresponding to X2 indicates that
it is a potential N-linked glycosylation site.
Interestingly, N-terminal sequence analysis of
KGF-b revealed an N-terminal amino acid sequence of
S-Y-D-Y-M-E-G-G-D-I-R-V- (SEQ ID N0:76), indicating that
it is an N-terminally truncated form of KGF that has
been proteolytically cleaved at the Arg23-Ser24 peptide
bond.
To further characterize purified KGF-a and
KGF-b, the protein was subjected to glycosidases
(neuraminidase, O-glycanase, and/or N-glycanase), using
_ known techniques (Sasaki et a1. (1987), J. Biol. Chem.,
262:12059-12076; Takeuchi et a1. (1988), J. Biol. Chem.,
263:3657-3663; Zsebo et a1. (1990), Cell, 63:195-201).
These data indicate that KGF-a contains N- and O-linked
carbohydrates, although the lower molecular weight form
CA 02202075 2000-07-26
WO 96/11949 PGTI1895I00971
- 53 -
of RGF-a probably contains only N-linked sugar.
Glycosidase treatment did not cause molecular weight
reduction for KGF-b, indicating that the molecule is
unglycosylated.
The glycos;ylation pattern of KGF-a was further
characterized :by mesa spectroscopy of the endoproteinase
Glu-C-generated peptides described above. Elucidation
of carbohydrate structure of glycopeptides by the
stepped orifice method of mass spectrometric analysis
has been successfully applied to other proteins
(Huddleston et a1. (1993), Anal. Chem., x:877-884; Carr
et a1. (1993), Prot. Sci., x:183-196). As confirmed by
the isolation of a non-glycosylated peptide, Thr22 seems
to be partiall:~r glycosylated. Similar mass
spectrometric ~3nalysi.s of Asnl4 suggested
microheterogeneity in glycosylation, with bi, tri and
tetra-antennar,r strucaures with varying degrees of
sialylation.
Table 3A siu~unarizes the KGF concentration to
stimulate [3H]~-thymidine incorporation of keratinocytes
at half-maxima:L rate (according to the method of Rubin
et a1. (1989), Supra). Interaction with the KGF
receptor was e~camined using isolated KGF receptor
membrane prepau:ations~ prepared from Balb/I~ mouse
epidermal kerat~inocyt.es (by the procedure described by
Massague (1983), J'. Biol. Chem., x$:13614-13620).
Specifically, various forms of KGF were diluted with 50
mM Tris-HC1, pFi 7.5, containing 0.2~ bovine serum
albumin so as t:o range in concentration from 0.8 ng to
100 ng per 50 ELI,. They were individually incubated with
the membrane preparation (75 ng/mL) and 125I_l~eled E.
coli-derived RGF (1.5 ng). Receptor binding and
competition exF~erimen.ts were performed at 4'C for 16
hr., after which time ssrnples were taken, centrifuged,
and washed twice with. the above diluent buffer to remove
unbound and non-specifically bound, labeled KGF.
CA 02202075 1998-03-06
WO 96111949 PGT/IB95100971
- 54 -
Samples were then counted for the remaining
radioactivity. Competition curves for receptor binding
between KGF samples and labeled KGF were constructed by
plotting percent uncompetition versus concentrations of
each KGF sample. Table 3B summarizes the KGF
concentration needed to achieve 60~ uncompetition
against the labeled E. coli derived KGF, expressed as
ng/mL.
Table 3A
KGF concentration to stimulate f3H1-thymidine
incorporation of keratinoc~rtes at half-maximal rate
Forms n /mL
E. coli KGF 10
KGF-a 30
KGF-b 30
Table 3B
KGF concentration to combete recebtor binding
with I125_labeled KGF at 60~ uncompetition rate
Forms n /mL
E. coli KGF 65.8
KGF-a 93.5
KGF-b 89.1
As shown in Table 3A, KGF-a and KGF-b
stimulate comparable [3H]-thymidine incorporation, with
the half-maximal rate being stimulated by approximately
ng/ml of either analog. Thus, the truncation does
not reduce biological activity of the molecule.
25 However, the two analogs have approximately 3-fold lower
activity than the E. coli-derived, full-length KGF. As
shown in Table 3B, radioreceptor assay uncompetition
CA 02202075 1998-03-06
WO 96/11949 PCTIIB95100971
- 55 -
experiments indicated that E. coli-derived KGF, KGF-a,
and KGF-b have similar receptor binding activity.
Example 4: In Vivo Biological Assay of KGF Polypeptides
Produced in E. coli and Mammalian Cell Culture
A single subcutaneous dose of KGF has been
shown to result in a dose-dependent rise in serum
cholesterol in mice within 24 hours. Native KGF, KGF-a,
C(1,15)S, ON15 and ~N23 were also evaluated for the
ability to raise the serum cholesterol level in a dose-
dependent manner.
Each treatment group contained five female
Balb/c mice (18-20 gms) obtained from CRL. The protein
was diluted with 0.9~ saline to achieve a final
injection volume of 100 ~1/mouse. Each mouse was
administered a single subcutaneous injection, at the
following doses:
CA 02202075 1998-03-06
WO 96/11949 PCTI~95100971
- 56 -
Grou Treatment Dose (m /k )
1 Native KGF 0.1
Native KGF 0.25
Native KGF 0.5
Native KGF 1
Native KGF 5
2 C(1,15)S 0.1
C(1,15)S 0.25
C(1,15)S 0.5
C(1,15)S 1
C(1,15)S 5
3 ~1V15 0 . 2 5
~1V15 0.5
~N15 1
~N15 5
4 ~N23 0.1
ON23 0.5
ON23 1
ON23 5
KGF-a 0.01
KGF-a 0.05
KGF-a 0.1
KGF-a 0.5
6 Saline Control -
Twenty-four hours after injection, the mice
were sacrificed and bled via cardiac puncture. Blood
samples were processed for the determination of serum
5 cholesterol.
CA 02202075 1998-03-06
WO 96/11949 PCTI1895100971
- 57 -
As shown in Figure 35, each tested KGF analog
was found to raise serum cholesterol in a dose dependent
manner. Also, there was no apparent difference in
bioactivity between any of the tested KGF analogs.
In Vivo Model of Diabetes
Chemically-induced diabetes mellitus models in
various animal species have been classically used to
study the disease and its treatment. Streptozotocin
induces diabetes in the mouse, rat, hamster, dog, and
monkey although studies in rats and mice are utilized
most. Junod et al., Proc. Soc. Exp. Pio. Med. 126:210-
205 (1967); Rerup, Pharm. Rev. 22:485-518 (1970); Rossini
et al., P.N.A.S. 74:2485-2489 (1977); and Ar'Rajab and
Ahren, Pancreas 8:50-57 (1993). In rats, doses of
streptozotocin from 45 to 70 mg/kg as a single
intravenous dose induce stable disease. Doses below 45
mg/kg induce a transient disease state which is
reversible. Within one day of streptozotocin injection,
the hyperglycemic state is induced. Blood insulin levels
remain essentially unchanged compared with normal rats;
however, the total content of insulin and C-peptide in
the pancreas is severely decreased. Rats manifest the
classic signs and symptoms of diabetes in humans:
increased blood glucose levels (hyperglycemia), glucose
in the urine (glucosuria), increased thirst (polydipsia),
increased urination (polyuria), increased appetite
(hyperphagia).
The studies described in this disclosure were
carried out with the streptozotocin-induced diabetes
model in Sprague-Dawley rats. Male rats weighing 200 260
grams at study initiation were used. Diabetes was
induced by a single intravenous injection of
streptozotocin at 50 mg of streptozotocin in sodium
citrate buffer per kg of body weight. Non-diabetic
CA 02202075 1998-03-06
WO 96/11949 PCT/IB95I00971
- 58 -
control rats received a single intravenous injection of
sodium citrate buffer for control purposes. KGF was
administered daily as a subcutaneous injection. The KGF
dose was 3 or 5 mg/kg/day, depending upon the experiment.
In the first experiment, KGF therapy was initiated two
days before diabetes, was induced and continued after the
induction of diabetes for a total of eight injections.
In the second and third experiments, KGF therapy
administered subcutaneously was initiated one day after
the induction of diabetes with streptozotocin. In the
fourth experiment, a 7 day course of KGF therapy was
initiated 7 days after streptozotocin treatment and the
animals were then followed for an additional 12 weeks.
In all experiments, except for the fourth experiment,
blood glucose levels, urine glucose levels and urine
volume were used as end points for analysis.
Additionally, water intake, urine C-peptide levels, or
total pancreatic insulin and C-peptide content were
measured in some experiments. In the fourth experiment,
the only assessed endpoint was blood glucose.
Because a large fraction of insulin is removed from the
circulation by the liver, measurement of peripheral
insulin concentrations reflect post-hepatic metabolism
events rather than insulin secretion from the pancreas.
Therefore, measurements of C-peptide are often made and
used as a peripheral marker of insulin secretion. C-
peptide is produced from the processing of pro-insulin to
insulin. Insulin and C-peptide are secreted from the
beta cells in equimolar amounts, and only a small amount
of C-peptide is extracted by the liver.
This study investigated the effect of rKGF on
streptozotocin-induced diabetes in Sprague-Dawley rats.
On day 0, groups of rats were exposed to either 45 or 50
mg/kg streptozotocin (STZ). Following these treatments,
non-fasting blood glucose levels were monitored daily to
assess the severity of the islet injury. On day 5, the
CA 02202075 2000-07-26
WO 96111949 PCT/1895/00971
- 59 -
STZ-treated animals were placed into one of two groups
(20/group) depending on the magnitude of hyperglycemia.
The dividing point 'was set at a blood glucose level of
300 mg/dl. p, group of non STZ-treated animals served as
controls. Or.~ day 7, IO animals from each hyperglycemic
group were given AN:23 (3 mg/kg/day) or PBS by
subcutaneous injection for 7 days. Blood glucose levels
were then monitored daily, every other day, or weekly and
are set forth in Figure 50. Note that STZ-treated
animals from both groups receiving dN23 had significant
declines in h~lood glucose during the 4N23 dosing period.
Importantly, the mean blood glucose drop experienced by
the STZ-treated animals from the <300 mg/dl starting
blood glucose group stabilized at about 150 mg/dl whereas
the blood glucose drop seen in the >300 mg/dl starting
blood glucose group was only transient. Note that the day
scale is non-linear.
While the present invention has been described
above both generall~t and in terms of preferred
embodiments, it is understood that other variations and
modifications will occur to those skilled in the art in
light of the description above.
